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Resumen y Abstract V
 
 
 
 
Resumen 
La retención de placenta afecta del 0.5 al 3% de las mujeres en el puerperio y constituye 
la mayor causa de mortalidad maternal debida a hemorragia postparto. Habitualmente, la 
retención de la placenta ha sido manejada con remoción manual o curetaje bajo 
anestesia. El objetivo de la presente revisión sistemática fué evaluar la efectividad y la 
seguridad de las prostaglandinas para el manejo médico de la placenta retenida. Se 
recuperaron 13016 referencias, de las cuales 3 fueron incluidas en esta revisión 
sistemática con meta-análisis. El uso de prostaglandinas se asoció a una mayor tasa de 
expulsión de la placenta sin remoción manual (RR 2.53 95% CI 1.66 to 3.86) y a un 
menor tiempo para expulsión de la placenta (MD -6.50 95% CI -11.19 to -1.81). Las 
prostaglandinas podrían ser una intervención efectiva para facilitar la expulsión de la 
placenta pero la calidad de la evidencia es limitada. No podemos recomendar ningun 
cambio en la práctica clínica.  
 
Palabras clave: “Placenta retenida”, “Hemorragia postparto”, “Retención de la placenta”, 
“Hemorragia uterina”, “Tercer estadío del parto”, Prostaglandinas”, “Oxitócicos”. 
 
A b s t r a c t  
Retained placenta affects 0.5%–3% of women following delivery and is a major cause of 
maternal death due to postpartum haemorrhage. Usually, the retained placenta has been 
managed by manual removal or curettage under anaesthesia. The objective of this 
systematic review was to assess the effects and safety of prostaglandins for management 
of retained placenta. A total of 13016 references were retrieved and finally 3 three studies 
were included in this systematic review with meta-analyses. Prostaglandins showed 
higher rate of expulsion of the placenta without manual removal (RR 2.53 95% CI 1.66 to 
3.86) and a lower time for delivery of the placenta (MD -6.50 95% CI -11.19 to -1.81). 
Prostaglandins might be an effective intervention to facilitate the delivery of the retained 
placenta, but we have very little confidence in the effect estimate. We can not 
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recommend any change in clinical practice until have high quality evidence. 
 
Keywords: “Retained placenta”, “postpartum hemorrhage”, “Placenta, retained”, “uterine 
hemorrhage”, “labor stage, third”, “prostaglandins”, “Oxytocics”. 
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1. Summary 
Background  
Retained placenta affects 0.5%–3% of women following delivery and is a major cause of 
maternal death due to postpartum haemorrhage. Usually, the retained placenta has been 
managed by manual removal or curettage under general anaesthesia (not immediately 
available in the majority of cases), which may be associated with haemorrhage, infection 
and uterine perforation. Medical management to facilitate the delivery of the retained 
placenta could potencially provide a safest alternative involving an earliest treatment and 
reducing the risk of complications.  
 
Objectives  
To assess the effects and safety of prostaglandins for management of retained placenta. 
 
Search strategy  
A systematic review using MEDLINE, EMBASE, CENTRAL (The Cochrane Library), AFI 
(African Index Medicus), AMI (Australian Medical Index), IMEMR (Index Medicus For The 
Eastern Mediterranean Region), IndMED, KoreaMed, LILACS, Scielo, IBECS, IMSEAR 
(Index Medicus For The South East Asian Region), Panteleimon,  WPRIM (Western 
Pacific Region Index Medicus), Scopus, Web of Knowledge, Proquest, dissertation.com, 
dissonline.de, openthesis.org,  Australian Digital Theses Program, openSIGLE, WHO 
Portal International Clinical Trials  Registry and metaRegister were searched. Additional 
studies were identified by contacting clinical experts and searching reference list of 
articles and recognized text books.   
 
Selection criteria 
Randomised controlled trials (RCTs) that included women who had a vaginal delivery of 
singleton live infants of 20 or more weeks of gestational age, with a retained placenta, 
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regardless of the management of the third stage of labour.  We excluded studies in which 
patients had a clear diagnosis of placenta accreta. 
 
Data collection and analysis  
Two review authors independently assessed the titles or abstracts of record retrieveded 
from search.  The investigator were masked to information about article such as the 
journal title, authors, institutions, the magnitude and direction of the results. Data from 
studies that met the inclusion criteria were independently extracted by two authors and 
the disagreement were solved by discussion or reviewed full text article.  Two review 
authors independently assessed risk of bias for each study using the criteria outlined in 
the Cochrane Handbook for Systematic Reviews of Interventions. 
 
Main results  
A total of 13016 references were retrieved and after excluded duplicates studies, a total of 
11760 titles were reviewed. Of these, 32 were initially screened as RCTs. Twenty eight 
studies were excluded and finally, we identified three studies that meet the inclusion 
criteria. The three studies included 141participants. Two studies were multicentric and 
one study had single location. All studies recruited patients who were admitted for hospital 
delivery, but one study also included patients who had home delivery. 
 
Prostaglandins showed higher rate of expulsion of the placenta without manual removal 
(RR 2.53 95% CI 1.66 to 3.86) and a lower time for delivery of the placenta (MD -6.50 
95% CI -11.19 to -1.81) compared with Oxytocin. Prostaglandins did not show any 
difference in terms of estimated blood loss (MD -258.04 95% CI -771.49 to 255.40), rate 
of maternal transfusion (relative risk (RR) 0.81 95% confidence interval (CI) 0.33 to 2.00) 
or duration of third stage of labour in minutes (MD -3.60 95% CI -21.57 to 14.37) 
compared with Placebo or Oxytocin or Manual removal. Prostaglandin showed identical 
rates of painful contractions (RR 2.12 95% CI 0.71 to 6.32) or any side effect defined as 
fever, sickness, vomiting, diarrhea, dizziness or flushes (RR 0.56 95% CI 0.12 to 2.49) 
compared with Placebo or Oxytocin or Manual removal. 
 
Authors’ conclusions  
Prostaglandins might be an effective intervention to facilitate the delivery of the retained 
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placenta avoiding surgical intervention, but we have very little confidence in the effect 
estimate. There is insufficient evidence on the safety and harms of this intervention. We 
can not recommend any change in clinical practice until have high quality evidence. 
 
Funding for the systematic review 
Department of Clinical Epidemiology, Faculty of Medicine, National University, Colombia.  
 
Systematic review registration number 
The methods of the analysis and inclusion criteria were specified in advance and 
documented in a protocol. Protocol number CE 098 Statement No.13. 

  
 
2. Background 
Description of the condition   
Postpartum haemorrhage (PPH) is an important cause of maternal mortality Sosa 2009 
and it accounts for nearly one-quarter of all maternal deaths world-wide with an estimated 
of 125,000 deaths per year Carroli 2008. The overall incidence of PPH is 6.09% with wide 
variations around the world; the highest rates occurs in Africa with 10.45%; North 
America, Europe, Oceania and Latin America had intermediate rates and the lowest rates 
are informed in Asia (2.55%) Carroli 2008. PPH is also associated with serious morbidity 
including blood transfusion, renal failure, coagulation deficiencies, anaemia and 
hysterectomy or other surgical procedures with their subsequent consequences on fertility 
Bodelon 2009. 
 
Retained placenta affects 0.5% to 3.0% of women following delivery, and is a major cause 
of maternal death due to postpartum haemorrhage. A further 15 to 20% of the PPH 
maternal deaths are due to retained placenta. After uterine atony, retained placenta is the 
second major indication for blood transfusion in the third stage of labour Owolabi 2008. 
Retained placenta is a potentially preventable cause of PPH Hoveyda 2001. 
 
There is no consensus as to the length of the third stage after which a placenta should be 
called ‘retained’. In Europe, manual removals of placentas are advised at anytime 
between 20 minutes and over one hour into the third stage Weeks 2008. The choice of 
timing is a balance between the PPH risk of leaving the placenta in situ, the likelihood of 
spontaneous delivery and the knowledge that the manual removal itself causes 
haemorrhage Rizwan 2009. Observational studies had demonstrated that a third stage 
longer than 30 minutes was associated with higher rate of postpartum haemorrhage, 
higher rate of transfusions and dilatation & curettage, compared with a third stage of 30 
minutes or less Deneux-Tharaux 2009. Because there was no increase in these medical 
complications until the third stage exceeded 30 minutes, it is suggest that above this time 
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an intervention is mandatory Combs 1991. 
 
Description of the intervention   
Prostaglandins (PG) are lipid molecules responsible for physiologic reactions that act as 
intermediaries in several processes involved during pregnancy including term labour, 
postpartum involution, and placental–fetal vascular dynamics. Their biosynthesis is limited 
by the activity of the enzyme arachidonic acid cyclo-oxygenase that catalyzes the 
transformation of arachidonic acid into prostaglandin G2 and the subsequent reduction of 
prostaglandin G2 to prostaglandin H2 Miller 2006. 
 
Prostaglandins have a potent uterotonic activity caused by their effect increasing 
intracellular calcium and activating myosin light chain kinase. The influx of calcium caused 
by prostaglandins, however, is probably caused by interaction with calcium channels, 
which is different from the mechanism of oxytocin Arias 2000.The role of the 
prostaglandin in the uterine muscle contractions during labour is well known. 
 
The prostaglandins receptors are present in both pregnant and nonpregnant uteri and 
their concentration in myometrial tissue increase at the beginning of labour. 
Prostaglandins have effects in myometrium and cervix, whereas the activity of oxytocin is 
limited to the uterine muscle and it is in fact strictly depended on calcium concentration 
Arias 2000. 
 
Prostaglandins F and E are the most important types of prostaglandins with uterotonic 
activity and relevant advantage compared with oxytocin in terms of biological activity. 
Prostaglandins E and F can be administered and are absorbed by any route including 
intravenous, oral, swallowed, sublingual, vaginal or intracervical administration with 
variable incidence of side effects Arias 2000. The notion that prostaglandins can be 
delivered to the retro-placental myometrium by any route has stimulated a lot of interest. 
 
How the intervention might work   
Ultrasound studies have improved the understanding of the third stage of labour. One 
study Herman 1993 demonstrated ultrasonographically that retro-placental myometrial 
contraction is paramount to produce shearing forces on the interface between the 
¡Error! No se encuentra el origen de la referencia. 9
 
placenta and myometrium, and to lead to its detachment; a prolonged third stage is due to 
contractile failure in the retro-placental area Weeks 2008 with difficulties for obstructing 
the blood flow through the arcuate and radial arteries to the placental fragments with the 
consequences of retained placenta and postpartum haemorrhage Weeks 2001. 
The advantages mentioned above allow prostaglandins to act specifically at the 
contractile failure area, stimulating contractions in the retro-placental myometrium Weeks 
2008. Medical management to facilitate the delivery of the retained placenta with 
prostaglandins could potentially provide a safest alternative involving an early treatment 
and reducing the risk of complications. 
 
Why it is important to do this review   
Usually, the retained placenta has been managed by manual removal or curettage with 
general anaesthesia (not immediately available in the majority of cases), which may be 
associated with haemorrhage, infection and uterine perforation. Medical management to 
facilitate the delivery of the retained placenta could be a safest alternative that avoids 
surgical intervention Sundaram 2009. Nowadays oxytocin umbilical vein injection and 
tocolysis have been the medical interventions systematically evaluated for treating 
retained placenta with little or no effect Nardin 2011 and limited evidence available for 
tocolysis Abdel-Aleem 2011. Actually, do not exist any systematic review that considers 
the paper of prostaglandins for the medical management of retained placenta. The 
prostaglandins or their analogues administered by any route could offer theoretical 
advances especially in developing countries. Is important to assess the effectiveness and 
safety of prostaglandins for management of retained placenta. Medical management to 
facilitate the delivery of the retained placenta with prostaglandins could potentially provide 
a safest alternative involving an early treatment and reducing the morbi-mortality 
associated with this condition. 
 
 
 
 
 
 

  
 
3. Objetives 
To assess the effects and safety of prostaglandins for management of retained placenta. 
 
 
 
 
 
 
 
 
 
 
 
 

  
 
4. Methods 
Criteria for considering studies for this review 
 
Types of study 
All published and unpublished randomised controlled clinical trials comparing the use of 
prostaglandins with placebo, no intervention, others oxytocics or with other interventions 
in the management of retained placenta after vaginal delivery of singleton live infants of 
20 or more weeks of gestational age, regardless of the management of the third stage of 
labour. We did not include quasi-randomised trials.  
 
Types of Participants 
All women having a vaginal delivery of singleton live infants of 20 or more weeks of 
gestational age with a retained placenta, regardless of the management of the third stage 
of labour. We define retained placenta as a third stage exceeding 20 minutes after 
delivery of the infant. We did exclude studies in which patients had a clear diagnosis of 
placenta accreta. 
 
Intervention and Comparisons 
Oxytocics are medicines used for increasing the contractility of the myometrial fiber. 
These include: prostaglandins, oxytocin, oxytocin agonists and ergot alkaloids. We did the 
following comparisons:  
 
1. Prostaglandins (different types, doses and routes of administration) alone for 
management of retained placenta, versus placebo. 
 
2. Prostaglandins (different types, doses and routes of administration) alone for 
management of retained placenta. versus no intervention. 
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3. Prostaglandins (different types, doses and routes of administration) for management of 
retained placenta versus oxytocin (different types, doses, frequency and routes of 
administration). 
 
4. Prostaglandins (different types, doses and routes of administration) for management of 
retained placenta versus oxytocin agonists (different types, doses, frequency and routes 
of administration). 
 
5. Prostaglandins (different types, doses and routes of administration) for management of 
retained placenta versus ergot alkaloids (different types, doses, frequency and routes of 
administration). 
 
6. Prostaglandins (different types, doses and routes of administration) for management of 
retained placenta versus other interventions. 
 
“Other interventions” include the use of manual removal, curettage, nitric oxide donors 
and uterine massage for management of retained placenta. 
 
Types of outcome measures 
We studied the following maternal outcomes. 
 
Primary Outcomes: 
1. Maternal mortality. 
2. Maternal transfusion. 
3. Serious maternal side effects of therapy.   
4. Expulsion of the placenta without manual removal. 
 
Secondary Outcomes: 
1. Postpartum haemorrhage or severe postpartum haemorrhage. 
2. Hypovolemic shock. 
3. Acute renal insufficiency. 
4. Hysterectomy or others surgical procedures.  
5. Endometritis or major puerperal infection or puerperal infection.  
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6. Hypotension or hypertension or coronary spasms or bronchospasm.  
7. Maternal admission to intensive care unit.   
8. Haemoglobin or hematocrit levels.  
9. Clinically or subjectively estimated blood loss.   
10. Duration of third stage of labour.  
11. Time for delivery of the placenta.      
12. Painful contractions.  
13. Fever or sickness or vomiting or diarrhea or dizziness or flushes.  
14. Maternal length of hospital stay.    
15. Maternal satisfaction with treatment.  
16. Cost-effectiveness of intervention. 
 
Search methods for identification of studies 
Electronic searches 
We searched in the three bibliographic databases considered to be the most important 
source to search for reports of trials: MEDLINE (Last search 31/05/2011), EMBASE (Last 
search 27/05/2011) and CENTRAL (Last search 17/05/2011) keeping in mind the 
resources and licenses available.  
 
In addition we searched national and regional databases because they can be an 
important source of additional studies from journals not indexed in other international 
databases. Those were: African Index Medicus, Australian Medical Index, Index Medicus 
For The Eastern Mediterranean Region, IndMED, KoreaMed, LILACS, Scielo, IBECS, 
Index Medicus For The South East Asian Region, Panteleimon and Western Pacific 
Region Index Medicus (Last search for all this databases 22/05/2011). 
 
For conference proceedings, dissertations and thesis we searched: Scopus, Web of 
Knowledge, Proquest, dissertation.com, dissonline.de, openthesis.org and Australian 
Digital Theses Program. For grey literature, we searched in openSIGLE database (Last 
search for all this databases 30/05/2011).  A reference list of articles and recognized texts 
books (Williams Obstetrics Chapters 17 & 35 Twenty-Third Edition and Creasy Resnik`s 
Maternal-Fetal Medicine Chapter 33 Sixth Edition) were also searched. 
Unpublished and ongoing studies. 
Formal letters to request for information were used to identify completed but unpublished 
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studies. A comprehensive list of relevant articles along with the inclusion criteria for the 
review were sent to the first author of the included studies, asking for any additional 
studies published or unpublished that might be relevant. International trials registers like 
WHO Portal International Clinical Trials  Registry (Last search 16/09/2011) and 
metaRegister (Last search 27/09/2011) were searched for ongoing studies (Searches 
Estrategies Appendix 1). All search strategies were peer reviewed as part of the 
systematic review process. 
 
Data collection and analysis 
 
Selection of studies 
Two review authors independently assessed the titles and abstracts of records retrieved 
from search to reduce the possibility that relevant reports were discharded.  The 
investigator were masked to information about article such as journal title, authors, 
institutions, and the magnitude and direction of the results.  
 
The final selection of studies to be included into the review were undertaken 
independently by two of the review authors and disagreement was solved by discussion, 
consult with a third author or review full text article.  We retrieved the full text of an article 
if there was any doubt as to whether the article should be excluded. Kappa statistic was 
calculated for measuring agreement between two authors making simple 
inclusion/exclusion decisions; Kappa value was 83% reflecting an excellent agreement 
(Appendix 2). 
 
Data extraction and management 
We designed a form to extract data. For eligible studies, two authors extracted data 
independently using a standard form; those authors were area and methodology experts. 
The disagreement about extracted data were solved by consensus, any disagreement 
that cannot be solved was addressed by contacting a third person (study or third author). 
If it was unsuccessful, the disagreement was reported in the review.   
 
The data that were extracted included the following: 
• Location of the study. Setting. 
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• Trial design. 
• Power calculation performed. 
• Inclusion and exclusion criteria defined. 
• Baseline information on the participants in order to have comparable intervention and 
control groups at entry (management of the third stage of labour, retained placenta 
definition, exclusion of patients with a clear diagnosis of placenta accreta). 
• Total number of intervention groups. 
• Types of interventions:  Prostaglandins (or analogues) types, doses, route of 
administration a duration intervention. 
• Method used to generate random allocation. 
• Methods used to maintain allocation concealment. 
• Number of women enrolled, randomised, excluded after randomisation, and analysed. 
• Use of any method of blinding of the researchers to the intervention in order to evaluate 
outcomes.  
• Adherence to planed intervention and other interventions in the groups under evaluation. 
• Number of participants lost to follow up in the two groups. 
• Outcomes stated in methods versus outcomes reported in results. 
• How secondary outcomes were defined 
• Differences between groups for outcome assessment. 
• Time of follow up of participants to measure outcomes.    
• How adverse event reports were validated. 
• Use of intention-to-treat analysis. 
• Funding sources, reported. 
• Ethical issues: use of signed informed consent and ethics approval. 
 
We collate and present this information in the tables ‘Characteristics of included studies’ 
and ’Characteristics of excluded studies’. We entered data into Review Manager (RevMan 
2011) and checked for accuracy. When information regarding any of the above was 
unclear, we attempted to contact authors of the original reports to provide further details. 
For a single ramdomised controlled clinical trial report we extracted data directly into a 
data collection form and in case of multiple reports, we extracted data from each report 
separately, then we combined information across data collection forms.  
Assessment of risk of bias in included studies  
Two review authors independently assessed risk of bias for each study using the criteria 
18 Prostaglandins for management of retained placenta
(A Systematic Review of Randomised Trials)
 
outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 
2008). We solved any disagreement by consensus or by involving a third assessor. Those 
assessing risk of bias were blinded to the names of authors, institutions, journals and 
results of studies and were theme and methodology experts. For collecting missing 
information we contacted the study investigators using open ended questions when 
asking for information about study design and conduction.  
 
1. Sequence generation (checking for possible selection bias) 
We described for each included study the method used to generate the allocation 
sequence in sufficient detail to allow an assessment of whether it produced comparable 
groups. We qualified the method as:  
 
a. Yes, low risk of bias (the investigators described a random component in the sequence 
generation process such as: random number table; computer random number generator; 
coin tossing, throwing dice, shuffling cards or envelopes). 
  
b. No, high risk of bias (the investigators described a non-random component in the 
sequence generation process such as: odd or even date of birth; hospital or clinic record, 
number or date of admission); or 
  
c. Unclear, uncertain risk of bias (insufficient information about the sequence generation 
process to permit judgment of “YES¨ or “NO”). 
 
2. Allocation concealment (checking for possible selection bias) 
We described for each included study the method used to conceal the allocation 
sequence in sufficient detail to determine whether intervention allocations could have 
been foreseen in advance of, or during enrolment, or changed after assignment. We 
qualified the method as:  
 
a. Yes, low risk of bias (participants and investigators enrolling participants could not 
foresee assignment because one of the following, or an equivalent method, was used to 
concel allocation: central allocation, sequentially numbered drug containers of identical 
appearance or sequentially numbered, opaque, sealed envelopes).  
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b. No, high risk of bias (participants and investigators enrolling participants could possibly 
foresee assignment because of the following method, was used: open random allocation 
schedule; unsealed or non-opaque or not sequentially numbered envelopes, alternation or 
rotation; date of birth, case record number); or 
 
c. Unclear, uncertain risk of bias (insufficient information about allocation concealment 
process to permit judgment of “YES¨ or “NO”). 
 
 
3. Blinding of participants, personnel and outcome assessors (checking for possible 
performance bias) 
We described for each included study the method used, if any, to blind study participants 
and personnel from knowledge of which intervention a participant received.  Any 
information relating to whether the intended blinding was effective to prevent systematic 
differences in the care provided, or in exposure to factors others than the interventions of 
interest were assessed. We qualified the method as:   
 
a. Yes, low risk of bias (any one of the following: No blinding, but the review authors judge 
that the outcome measurement are not likely to be influenced by lack of blinding; blinding 
of participants and key study personnel ensured and unlikely that the blinding could have 
been broken; either participants or some key study personnel were not blinded but 
outcome assessment was blinded and the non-blinded of others unlikely to introduce 
bias).  
 
b. No,  high risk of bias (any one of the following: No blinding or incomplete blinding, and 
the  outcome  measurement is likely  to be influenced by lack of blinding;  blinding of key 
participants and personnel attempted, but likely that the blinding could have been  broken; 
either participants or some key study personnel were not blinded); or 
 
c. Unclear, uncertain risk of bias (insufficient information to permit judgment of “YES¨ or 
“NO” or the study not address this outcome). 
 
4. Incomplete outcome data (checking for possible attrition bias through withdrawals, 
dropouts, protocol deviations). Describe the completeness of outcome data for each main 
20 Prostaglandins for management of retained placenta
(A Systematic Review of Randomised Trials)
 
outcome, including attrition and exclusion from the analysis; whether attrition and 
exclusions were reported; the numbers in each intervention group (compared with total of 
randomized participants); reasons for attrition/exclusions reported and any re-inclusions in 
analysis performance by the review authors. We qualified the method as:   
 
a. Yes, low risk of bias (no missing outcome data; reasons for missing outcome data 
unlikely to be related to true outcome; missing outcome data balanced in numbers across 
intervention groups, with similar reasons for missing data across groups; for dichotomous 
data the proportion of missing outcomes compared with observed event risk not enough 
to have a clinically relevant impact on the intervention effect estimate; for continuous data, 
plausible effect  size among missing outcomes not enough to have a clinically  relevant 
impact on observed effect size; missing data have been imputed using appropriate 
methods).  
 
b. No,  high risk of bias (reasons for missing outcome data likely to be related to true 
outcome; for dichotomous data the proportion of missing outcomes  compared with 
observed  event risk enough to induce clinically  relevant bias in intervention effect 
estimate; for continuous data, plausible effect size among missing outcomes  enough to 
induce clinically relevant bias in observed effect size; potentially inappropriate application 
of simple imputation; “As-treated” analysis done with substantial departure of the 
intervention received from that assigned at randomization); or 
 
c. Unclear, uncertain risk of bias (insufficient reporting of attrition/exclusion to permit 
judgment of “YES¨ or “NO” or the study not address this outcome). 
 
5. Selective outcome reporting  
State how the possibility of selective outcome reporting was examined by the review 
authors, and what was found.  We qualified the method as:   
 
a. Yes, low risk of bias (The study protocol is available and all the study's pre-specified 
outcomes  that are of interest in the review have been reported in the pre-specified way; 
the study protocol is not available but it is clear that the published reports included all 
expected outcomes, including those that were pre-specified).  
Capítulo 21
 
 
b. No, high risk of bias (Not all the study's pre-specified primary outcomes have been 
reported; one or more primary outcomes is reported using measurements, analysis 
methods or subsets of data that were not pre-specified; one or more reported primary 
outcomes were not pre-specified, one or more outcomes of interest in the review are 
reported incompletely so that they cannot be entered in a meta-analysis; the study report 
fails to include results for a key outcome); or 
 
c. Unclear, uncertain risk of bias (insufficient to permit judgment of “YES¨ or “NO”). 
 
6. Other sources of bias 
State any important concerns about bias not addressed in the other domains of the tool. 
We qualified the method as: 
 
a. Yes, low risk of bias (The study appears to be free of other sources of bias.).  
 
b. No, high risk of bias (The study had a potential source of bias related to the specific 
study design; stopped early due to some data-dependent process, had extreme baseline 
imbalance; had been claimed to have been fraudulent or some other problem); or 
 
c. Unclear, uncertain risk of bias (insufficient information to assess whether an important 
risk of bias exists). 
 
7. Overall risk of bias  
We made explicit judgments about whether studies are at high risk of bias, according to 
the criteria given in the Handbook. With reference to (1) to (6) above, we assessed the 
magnitude and direction of the bias and whether we consider it is likely to impact on the 
findings. We planned to explore the impact of the level of bias through undertaking 
sensitivity analysis for show how conclusions might be affected if studies at high or 
unclear risk of bias were included in analysis (based on key bias domains).  
 
Measures of treatment effect  
Dichotomous data  
For dichotomous data, we presented results as summary risk ratio (RR) with 95% 
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confidence intervals (CI). The RR as relative effect measure has consistency, works well 
with small or big rate of events, and is easier to interpret in clinical practice. 
      
Continuous data  
For continuous data, we used the mean difference if outcomes are measured in the same 
way among trials. We used the standardized mean difference to combine trials that 
measure the same outcome, but use different methods.  
 
Dealing with missing data  
For included studies, we noted levels of attrition. We planned to explore the impact of 
include studies with high levels of missing data in the overall assessment of treatment 
effect by using sensitivity analysis. For all outcomes we carried out analysis, as far as 
possible, on an intention-to-treat basis; we attempted to include all participants 
randomised to each group in the analysis, regardless of whether or not they received the 
allocated intervention. The denominator for each outcome in each trial was the number 
randomised minus any participants whose outcomes are known to be missing.  
 
Assessment of heterogeneity  
We used the I² statistic to measure heterogeneity among the trials in each analysis. We 
considered that heterogeneity might not be important if I² was less than 40%. If we identify 
substantial heterogeneity we explored it by prespecified subgroup analysis.  
 
Assessment of reporting biases  
If we suspected reporting bias we attempted to contact study authors for missing outcome 
data. If this was not possible, and the missing data are thought to introduce serious bias, 
we planned to explore the impact of include such studies in the overall assessment of 
results by a sensitivity analysis.  
 
Detecting publication biases. 
For detect publication biases, we planned to use tests for funnel plots asymmetry 
according to statistician advice and then explored others possible sources of asymmetry. 
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Data synthesis  
We carried out statistical analysis using the Review Manager software. We planned to 
use fixed-effect Mantel-Haenszel meta-analysis for combining dichotomous data and 
fixed-effect inverse variance meta-analysis for combining continuous data where trials 
were examining the same intervention, and the trials’ populations and methods were 
judged sufficiently similar. Where we suspected clinical or methodological heterogeneity 
between studies sufficient to suggest that treatment effects may differ between trials we 
planned to use random-effects meta-analysis.  
 
If substantial heterogeneity was identified in a fixed-effect meta-analysis we repeated the 
analysis using a random-effects method.  
 
Subgroup analysis and investigation of heterogeneity  
We planned to carry out the following subgroup analysis:  
1. Compare the different prostaglandin type. 
2. Compare the different prostaglandin administration route. 
 
We used the following outcome in subgroup analysis:  Expulsion of the placenta without 
manual removal.   
 
For fixed-effect meta-analysis we conducted planned subgroup analysis classifying the 
whole trials by interaction tests (Deeks 2008). For random-effects meta-analysis we 
planned to assess differences between subgroups by inspection of the subgroups’ 
confidence intervals; non-overlapping confidence intervals indicate a statistically 
significant difference in treatment effect between the subgroups.  
 
Sensitivity analysis  
We planned to perform sensitivity analysis for aspects of the review that might had 
affected the results, for example, where there was risk of bias associated with the quality 
of some of the included trials or used definition of prolonged third stage. We also planned 
to carry out sensitivity analysis to explore the effects of fixed or random-effects analysis 
for outcomes with statistical heterogeneity.  
  
 
5. Ethical Issues 
The objective of this protocol was to obtain value useful information for improving science 
knowledge in the medical management of retained placenta with prostaglandins; this is an 
unsolved topic and could potentially provide a safest alternative involving an earliest 
treatment and reducing risks of complications. We planned to use the skills and 
knowledge obtained with this systematic review in the implementation of relevant policies 
and programs realted to maternal health, contributing to the development of new items in 
sexual and reproductive health for decreasing the unacceptably high numbers of 
preventable mortality and morbidity among mothers in developing countries, with the use 
of best evidence. 
 
According to Colombian Resolution Number 8430 of 1993, this is an investigation without 
risk. Meta-analysis are an special type of studies that use a retrospective methodology 
based in previous articles and don´t imply any intervention or change about biological, 
physiological, psychological o socials variables. For the Meta-analysis, the subjects under 
investigation are clinical trials and not patients directly.  Also, ethical issues were critically 
appraisal in each of included clinical trials with the domain “Other sources of bias” of the 
tool “assessment of risk of bias in included studies”.  
 
The methods of the analysis and inclusion criteria were specified in advance and 
documented in a protocol. Protocol number CE 098 Statement No.13. 
  
 
6. Results 
Description of studies  
See: Characteristics of included studies; Characteristics of excluded studies; 
Characteristics of studies awaiting classification.  
 
For a detailed description of studies see table of Characteristics of included studies and 
excluded studies. The following text summarizes the main characteristics. 
  
A total of 13016 references were retrieved and after excluded duplicates studies, a total of 
11760 titles were reviewed. Of these, 32 were initially screened as RCTs. Twenty eight 
studies were excluded for the following reasons: 13 studies were not randomized 
controlled trial, 15 studies were duplicates and 1 study included a different intervention. 
 
Finally, we identified three studies that meet the inclusion criteria (Appendix 3). The main 
characteristics of the included studies are detailed in the table Characteristics of included 
studies. All studies were published manuscripts.  
 
All studies had small samples; the largest trial includes 54 participants (Rogers 2007). 
One study (J. van Beekhuizen 2006) was developed in two phases, the first one was a 
randomized phase comparing prostaglandin with placebo; and the second one had a non-
randomised assignation to the branch of prostaglandin. In order to carry out the analysis 
planned in our a priori protocol, we just included the randomised phase results. The 
studies were from three countries: Israel (Bider 1996), The Netherlands (J. van 
Beekhuizen 2006) and Hong Kong (Rogers 2007). All trials were published in English. 
 
Population 
The three studies included 141participants. Two studies were multicentric (J. van 
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Beekhuizen 2006; Rogers 2007) and one study (Bider 1996) had single location. All 
studies recruited patients who were admitted for hospital delivery, but one study (J. van 
Beekhuizen 2006) also included patients who had home delivery. 
 
Two studies (Bider 1996; Rogers 2007) included only women having singleton pregnancy 
and one study (J. van Beekhuizen 2006) do not mentioned this variable. One study 
(Rogers 2007) just included pregnancies beyond 37 weeks of gestation; another one (J. 
van Beekhuizen 2006) included pregnancies with gestational age ≥ 28 weeks. One study 
(Bider 1996) included two preterm pregnancies equivalent to 6% of study population 
(gestational age not mentioned).  
 
Two studies (Bider 1996; J. van Beekhuizen 2006) included women with history of prior 
manual removal of placenta or cesarean delivery or curettage.  One study (J. van 
Beekhuizen 2006) included 6 patients that received intervention after operative vaginal 
delivery. All studies included women regardless of parity. One study (Rogers 2007) do not 
mentioned relevant history.  
 
During delivery, all patients received active management of labor; two studies used 
oxytocin (Bider 1996; J. van Beekhuizen 2006) and one study (Rogers 2007) used 
syntometrine or oxytocin. 
 
Interventions 
The interventions, agents and uterotonic drugs used in these trials include: saline solution 
alone injected into the umbilical vein or intravenous infusion, oxytocin plus saline solution 
injected into the umbilical vein, prostaglandin plus saline solution injected into the 
umbilical vein and prostaglandin by intravenous infusion. One study (Bider 1996) included 
a group with manual removal of placenta. 
 
Prostaglandin plus saline solution versus saline solution alone was compared in two trials 
(Bider 1996; Rogers 2007) including 51 patients. Prostaglandin plus saline solution versus 
oxytocin plus saline solution in two trials (Bider 1996; Rogers 2007) including 62 women.  
Prostaglandin versus saline solution alone in one study (J. van Beekhuizen 2006) 
including 50 patients and prostaglandin plus saline solution versus manual removal of the 
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retained placenta in one study (Bider 1996) including 19 women. 
 
The volume injected into the umbilical vein was 20 mL in one trial (Bider 1996) whereas 
one study used a higher volume: 30 mL (Rogers 2007); the other study used intravenous 
infusion but do not mentioned the infused volume. 
 
Prostaglandin doses used were 20 mg of Prostaglandin F2α (Bider 1996), 800 mcg of 
Prostaglandin E1 analog (misoprostol) (Rogers 2007), and 250 mcg of Prostaglandin E2 
analog (sulprostone) (J. van Beekhuizen 2006). One study used 30 IU (Bider 1996) and 
the other one used 50 IU of oxytocin (Rogers 2007).  
 
Time to intervention administration  
The time to intervention administration after delivery of the newborn was 45 minutes in 
one study (Rogers 2007) and 60 minutes in the others (Bider 1996; J. van Beekhuizen 
2006). 
 
Limit time for manual removal of the placenta  
The limit time for manual removal of the placenta was 30 minutes in all trials. 
 
Outcomes 
Although most studies reported at least one prespecified primary outcome of this review, 
there were some differences in reporting and definition of the outcomes. All trials recorded 
the need or not of manual removal of the placenta; two studies informed complications 
(abdominal pain or painful contractions, dizziness, flushes or nausea)  (Bider 1996; J. van 
Beekhuizen 2006); two studies informed blood loss  (mL) (Bider 1996; J. van Beekhuizen 
2006), one study informed duration of third stage (min) (Rogers 2007) and other one 
informed expulsion time (min) (Bider 1996). One study reported blood transfusion (J. van 
Beekhuizen 2006); one study recorded other medicals interventions (nitroglycerine or 
isoflurane) (J. van Beekhuizen 2006) and only one trial registered febrile morbidity (Bider 
1996). Total length of in-patient stay was reported in one clinical trial (Bider 1996).  
 
Length of follow up  
In one trial participants were followed up until discharge from the institution (Bider 1996). 
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In the others the timing of follow up was not pre-specified. 
 
Risk of bias in included studies  
Selection bias 
 
Two trials adequately reported the random method generation by using a computer 
generated randomization list, and the concealment of allocation method by using 
sequentially numbered sealed envelopes or sequentially numbered drugs containers, 
respectively, making selection bias at entry unlikely (J. van Beekhuizen 2006; Rogers 
2007). In another trial (Bider 1996), the sequence generation method was adequate by 
using a computer generated randomization list, but did not report how concealment of 
allocation was performed; the possibility of selection bias at entry to the trial is likely, 
especially for one group (manual removal of placenta) that included three patients, 
assigned because of their excessive bleeding; therefore, this study could be prone to 
selection bias.  
 
Blinding 
The study of Bider 1996 is likely to suffer performance bias because they did not describe 
the masking procedure between the arms of the trial. In an effort to diminish the bias, a 
time limit of 30 minutes, for manual removal of placenta was established, but they did not 
measure compliance to ensure all participants in the trial received the intervention 
according to the trial protocol. The study of J. van Beekhuizen 2006 is unlikely to suffer 
performance bias because the physicians were not aware of the treatment given and a 
time limit of 30 minutes was established for manual removal of the placenta. 
  
The study of Rogers 2007 is prone to performance bias because the physicians could be 
aware of the treatment given, as solutions were not similar in color. In an effort to diminish 
the bias, a time limit of 30 minutes, for manual removal of placenta was established, but 
they did measure compliance to ensure all participants in the trial received the 
intervention according to the trial protocol.  
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Attrition bias 
There were not withdrawals or loss of participants to follow up between groups in one trial 
(Rogers2007), so the likelihood of attrition bias is very low. In other study (J. van 
Beekhuizen 2006) 15,2% of the women were excluded from the analysis for violations of 
the treatment protocol. One patient withdrew her consent; 1 patient mentioned after 
inclusion that she had a cardiac condition that was a contraindication to participate in the 
study; in 3 patients, the placenta was expelled within 60 minutes after delivery of the 
infant before trial medication, and in 4 patients, blood loss exceeded 1000 mL before 
medication; authors did a “As-treated” analysis because they only included the results 
from those patients who had both been assigned randomly and who had actually received 
the trial medication; this trial a high risk of attrition bias. 
 
The remaining trial (Bider 1996), did not state number randomized, neither the number of 
withdrawals and follow-up lost and none explanation about the reasons was provided, 
leaving unclear the risk of attrition bias into the trial. 
 
Selective outcome reporting 
For all studies the study protocol is not available and it is unclear if the published reports 
included all expected outcomes, including those that were pre-specified. The reports do 
not have sufficient information to permit judgment of “Yes” or “No”. 
 
Other bias 
One study appear to be free of other sources of bias (Bider 1996) and the other studies 
(J. van Beekhuizen 2006; Rogers 2007) had a potential source of bias related to formal 
stopped early rule due to apparent benefit. In summary, according to the criteria applied 
for the sensitivity analysis, all the trials were of poor methodological quality or there was 
insufficient information for inclusion into the high-quality group. (Figure 1; Figure 2). 
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Figure 1. Methodological quality graph: review authors’ judgements about each 
methodological quality 
item presented as percentages across all included studies. 
 
  
 
Figure 2. Methodological quality summary: review authors’ judgements about each 
methodological quality item for each included study 
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Effects of interventions 
During the systematic review, we faced to an unexpected event; we identified one clinical 
trial that randomised participants to four intervention groups: oxytocin, saline solution, 
prostaglandin and manual removal (Bider 1996), and other one which randomised 
participants to three intervention groups: oxytocin, saline solution and prostaglandin 
(Rogers 2007). We proceeded according to our statistical advisor and the methods 
described in the Handbook Section 16.5. First, we assessed which intervention groups 
were relevant, and, in order to avoid confusion for the reader, we wrote all intervention 
groups of the study in the table of “characteristics of included studies”. We also provided 
detailed description of intervention groups relevant to the review and only these groups 
were used in analysis.  
 
Finally, in order to overcome a unit-of-analysis error for a study that could contribute 
multiple, correlated, comparison, we combined all relevant experimental intervention 
groups of the studies into a single group and also combined all relevant control 
intervention groups into a single control group, in order to create a single pair-wise 
comparison, acording to the Cochrane systematic review of Nardin 2011 which compared 
the use of saline solution alone or with oxytocin for treating retained placenta and found 
no differences in any of the assessed outcomes. Following this assumption, we carried 
out a total of 4 meta-analysis (more than one trial analyzed); while the other three report 
results correspond to single-trial analysis. 
 
Comparison 1: Maternal Transfusion 
We reported results correspond to single-trial analysis (J. van Beekhuizen 2006). We did 
not find a significant difference in the rate of maternal transfusion (1 RCTs, 50 
participants; RR 0.81 95% CI 0.33 to 2.00; I2 Not applicable) (Figure 3). 
 
Figure 3. Forest plot of comparison: 1 Maternal outcome: 1.1 Maternal Transfusion. 
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Comparison 2: Expulsion of the placenta without manual removal 
We reported results corresponding to meta-analysis of three studies (Bider 1996; J. van 
Beekhuizen 2006; Rogers 2007). There was a significant difference favoring 
prostaglandins in the rate of expulsion of the placenta without manual removal (3 RCTs, 
132 participants; RR 2.53 95% CI 1.66 to 3.86; I2 0%) (Figure 4). 
 
 
Figure 4. Forest plot of comparison: 1 Maternal outcome: 1.2 Expulsion of the placenta 
without manual removal 
 
 
 
 
Comparison 3: Estimated Blood Loss (mL)  
We reported results corresponding to meta-analysis of two studies (Bider 1996; J. van 
Beekhuizen 2006). We did not find a significant difference in estimated blood loss (2 
RCTs, 87 participants; MD -258.04 95% CI -771.49 to 255.40; I2 88%) (Figure 5). 
 
Figure 5. Forest plot of comparison: 1 Maternal outcome: 1.3 Estimated Blood Loss 
(ml).  
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Comparison 4: Duration of third stage of labour (min)  
We reported results corresponding to single-trial analysis (Rogers 2007). We did not find 
a significant difference in duration of third stage of labour in minutes (1 RCTs, 54 
participants; MD -3.60 95% CI -21.57 to 14.37; I2 Not applicable) (Figure 6). 
 
 
Figure 6. Forest plot of comparison: 1 Maternal outcome: 1.4 Duration of third stage of 
labour (min) 
 
 
 
 
Comparison 5: Time for delivery of the placenta (min)  
We reported results corresponding to single-trial analysis (Bider 1996). We found a 
significant difference in time for delivery of the placenta (1 RCTs, 21 participants; MD -
6.50 95% CI -11.19 to -1.81; I2 Not applicable) (Figure 7). 
 
Figure 7. Forest plot of comparison: 1 Maternal outcome: 1.4 Time for delivery of the 
placenta (min) 
 
 
 
 
Comparison 6: Painful Contractions  
We reported results correspond to meta-analysis of two studies (Bider 1996; J. van 
Beekhuizen 2006). We did not find a significant difference in painful contractions (2 RCTs, 
87 participants; RR 2.12 95% CI 0.71 to 6.32; I2 0%) (Figure 8). 
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Figure 8. Forest plot of comparison: 1 Maternal outcome: 1.5 Painful Contractions. 
 
 
Comparison 7: Fever or sickness or vomiting or diarrhea or dizziness or flushes 
We reported results corresponding to meta-analysis of two studies (Bider 1996; J. van 
Beekhuizen 2006). We did not find a significant difference in fever, sickness, vomiting, 
diarrhea, dizziness or flushes (2 RCTs, 87 participants; RR 0.56 95% CI 0.12 to 2.49; I2 
0%) (Figure 9). 
 
Figure 9. Forest plot of comparison: 1 Maternal outcome: 1.6 Fever or sickness or 
vomiting or diarrhea or dizziness or flushes. 
 
 
 
 
Subgroup analysis and investigation of heterogeneity  
We planned to carry out the following subgroup analysis: Compare the different 
prostaglandin types and the different administration routes, in order explain the possible 
heterogeneity to the outcome “Expulsion of the placenta without manual removal”, 
however we did not find significant heterogeneity or subgroup that could affect the results. 
For fixed-effect meta-analysis we conducted planned subgroup analysis classifying the 
whole trials by interaction tests as described by Deeks. (Figure 10 and 11). 
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Figure 10. Forest plot of comparison: 1 Maternal outcome: 1.2 Expulsion of the placenta 
without manual removal by prostaglandin type. 
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Figure 11. Forest plot of comparison: 1 Maternal outcome: 1.2 Expulsion of the placenta 
without manual removal by prostaglandin administration route. 
 
 
 
Sensitivity analysis  
A sensitivity analysis  was caried out to explore the effect of trials definition of prolonged 
third stage into the significance of the results for expulsion of the placenta without manual 
removal. We did not find any change in our conclusions.  
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Figure 12. Forest plot of comparison: 1 Maternal outcome: 1.2 Expulsion of the placenta 
without manual removal by third stage definition. 
 
 
 
 
Additionally, we made a sensitivity analysis in order to evaluate the significance of the 
results for expulsion of the placenta without manual removal, based on our decision of 
integrate all relevant treatment and comparator groups in one. We did not find any change 
in our conclusions.   
 
 
Figure 13. Forest plot of comparison: 1 Maternal outcome: 1.2 Expulsion of the placenta 
without manual removal by unit-of-analysis. 
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Figure 14. Forest plot of comparison: 1 Maternal outcome: 1.2 Expulsion of the placenta 
without manual removal by unit-of-analysis. 
 
 
 
 
 
Finally, we proposed to perform a sensitivity analysis to explore the effect of trials quality, 
but in consistency to the criteria applied for risk of bias, all the trials were of poor 
methodological quality and there was impossible to execute this analysis 
 
  
 
7. Discussion 
Summary of main results 
Prostaglandins were superior to Placebo or Oxytocin in achieving the expulsion of the 
placenta without manual removal; there was also a decrease in the time for delivery of 
placenta when prostaglandin was compared with Oxytocin. The frecuencies of maternal 
transfusion, estimated blood loss, duration of third stage of labour, painful contraction or 
any others adverse events were not different between groups.   
 
Overall completeness and applicability of Evidence 
Although a comprehensive research in order to retrieved all published and unpublished 
randomized clinical trials, this systematic review included a little number of patients, the 
data are incomplete, and we did not find studies that evaluated some relevant clinical 
outcomes; for example, no one study assessed the proposal intervention impact over 
maternal mortality incidence, postpartum haemorrhage, hypovolemic shock, acute renal 
insufficiency, maternal admission to intensive care unit, maternal satisfaction with 
treatment or cost-effectiveness of intervention. We neither found some study focus on 
comparison of the usual care and medical management with prostaglandins. The 
effectiviness and safety of the medical management with prostaglandins compared with 
manual removal on retained placenta, is still an unknown answer.  
 
The applicability of the evidence outside the research setting is limited; however these 
studies were all conducted in clinical settings quite similar, and included a variety of 
clinical situations. The interventions in the review are uncommon, being the prostaglandin 
E1 analog (Misoprostol) the only available in our clinical setting; besides, the 
administration route requires some medical supplies and additional training.  
 
 
40 Prostaglandins for management of retained placenta
(A Systematic Review of Randomised Trials)
 
Quality of the evidence 
Overall the studies had a high risk of bias and the evidence quality is very low (Appendix 
4). We have very little confidence in the effect estimate; the true effect is likely to be 
substantially different. The quality of evidence is very low by studies limitations (lack of 
allocation concealment, lack of blinding, failure to adhere to the intention-to-treat principle 
and stopping early for benefit), inconsistency (unexplained variability in some results), 
indirectness (differences between the interventions of interest and those studied) and 
imprecise results (few patients and outcome events with wide confidence intervals). 
 
We could not evaluate publication bias, because there was not enough number of 
included studies and the trials were small. There is some concern about publication bias. 
  
 
8. Authors´Conclusions 
Implications for practice 
Prostaglandins might be an effective intervention for the management of placenta 
retained, to facilitate the delivery of the retained placenta avoiding surgical intervention, 
but we have very little confidence in the effect estimate. There is insufficient evidence on 
the safety and harm of this intervention. We can not recommend any change in the 
clinical practice until the existence of more evidence with a high quality. 
Implications for research 
There is an urgent need for better quality randomised controlled trials on treatments for 
retained placenta, particularly comparing manual removal and prostaglandins. The issue 
of the retained placenta lends itself methodological problems because it is an uncommon 
condition and it is life threatening. It is therefore expected that among the clinical trial 
published, exist a lack of allocation concealment, a lack of blinding, a failure to adhere to 
the intention-to-treat principle, and imprecise results or they were stopped early for 
benefit. 
Further research should focus on compare manual removal and medical management 
with prostaglandins, with complete reporting of the most important clinical outcomes. 
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Tables 
Characteristics of studies 
Characteristics of Included Studies [ordered by year of study] 
 
Characteristics of included studies [Bider 1996]. 
Methods • Location of the study: The Chain Sheba Medical Center, Tel Hashomer. 
Israel.  
• Trial design: Randomized clinical trial, parallel, four arms. 3.5 years of study. 
Ending September 1992. 
• Power calculation performed: Unclear. Comment: Probably not done.  
• Method used to generate random allocation: “…We studied all the patients 
prospectively and by computerized randomization, except for three who were 
from the manual group because of their excessive bleeding and could 
therefore not be randomized…” Comment: Probably done. 
• Methods used to maintain allocation concealment: Unclear. 
• Number of women enrolled, randomised, excluded after randomisation, and 
analysed: Women enrolled 37. Women randomised 37 and women analysed 
37. Comment: Unclear. 
• Use of any method of blinding of the researchers to the intervention in order 
to evaluate outcomes.  Success rate: Unclear, objective outcome Comment: 
low risk of bias. Expulsion time (min): Unclear, objective outcome. Comment: 
low risk of bias. Blood loss (ml): Unclear, probably subjectively estimated, 
blinding probably not done. Comment: high risk of bias. Complications (fever, 
abdominal pain): Unclear, probably subjectively estimated, blinding probably 
not done. Comment: high risk of bias.  
• Number of participants lost to follow up in the four groups: Unclear.  
• Use of intention-to-treat analysis: yes. Comment: all patients were analysed 
according to assigned intervention.  
• Funding sources, reported: No.  
• Ethical issues (use of signed informed consent and ethics approval): 
Informed consent was obtained in all cases. Comment: probably done. 
 
Participants • Inclusion and exclusion criteria defined.  
Women with diagnosis of retained placenta during study period in the 
reference hospital. Singleton pregnancy.  
• Setting: In-patients.  
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• Baseline information on the participants in order to have comparable 
intervention and control groups at entry (eligibility criteria, management of the 
third stage of labour, retained placenta definition, exclusion of patients with a 
clear diagnosis of placenta accreta). Table 1 summarizes some demographic 
data among the four groups. There were no significant differences. 
 
Thirty seven patients. Thirty five full term, two preterm, four had uterine 
scarring and two had history of retained placenta.  All patients were 
multiparas. 
 
“…If the patient had not received oxytocin augmentation during labour, 10 UI 
oxytocin was injected intravenously after expulsion of the infant…” 
 
“…Retained placenta was diagnosed when separation did not occur 1 hour 
after delivery and umbilical cord clamping…” Comment: after this period the 
interventions were administered.  
 
“…If placental expulsion did not occur with 30 minutes either PGF2α or 
oxytocin were injected randomly…” Comment: Time limit to placental 
expulsion after any intervention. 
 
Interventions • Total number of intervention groups: Four arms. 
• Types of interventions:  Prostaglandins types, doses, route of administration 
a duration intervention.  
Group one: 20 ml solution containing 20 mg PGF2α. 
Group two: 20 ml solution containing 30 units of oxytocin. 
Group three: 20 ml of normal saline alone. 
Group four: manual removal of the placenta. 
 
The injection was administered within 15 seconds into umbilical vein of the 
cord 1 cm from the introitus just proximal to the cord clamp. 
  
•Adherence to planed intervention and Other interventions in the groups 
under evaluation: the management after injection was observation, Signs of 
placental separation (suden gush of blood, umbilical cord protruding from the 
vagina, and changes in the uterine size and position) were recorded. Gentle 
traction of the cord for final expulsion was used.  
Outcomes  • Outcomes stated in methods versus outcomes reported in results: 
Outcomes stated in methods. 
 
• How Outcomes such as: postpartum haemorrhage, severe postpartum 
haemorrhage, hypovolemic shock, acute renal insufficiency, duration of third 
stage of labour,  time for delivery of the placenta, maternal satisfaction with 
treatment and cost-effectiveness of intervention were defined: 
 
Time for delivery of the placenta: In minutes. 
 
Blood loss: In milliliters, probably subjectively estimated.  
 
• Time of follow up of participants to measure outcomes: maternal mortality, 
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maternal transfusion, expulsion of the placenta without manual removal, 
hysterectomy or others surgical procedures, endometritis, major puerperal 
infection, puerperal infection, maternal admission to intensive care unit, 
haemoglobin or hematocrit levels, maternal length of hospital stay:    
 
Success rate: Objective outcome. Signs of placental separation and changes 
in uterine size and position were recorded when observed. 
 
Thirty three of the patients had normal courses of immediate postpartum 
periods and were discharged from hospital period and were discharged from 
the hospital after 72 hours accordance with our routine management. Four 
patients were discharged 1 to 3 dyas later because of febrile morbidity (2 
cases) and anemia (2 cases). These patients were managed by observation 
and conservative management. It was not clear at which group they belong. 
 
• How adverse event reports (painful contractions, fever,  sickness,  vomiting, 
diarrhea, dizziness, flushes, serious maternal side effects of therapy, 
hypotension, hypertension, coronary spasms or bronchospasm) were 
meassured: 
 
Complications (fever, abdominal pain): Unclear definition, probably 
subjectively estimated. Complications were minor, and included febrile 
morbidity in two patients (one in the PGF2 group, and one in the oxytocin 
group), and abdominal pain in four patients (3 in the PGF2 group, and one in 
the oxytocin group). Loss of blood occurred in two of the oxytocin group and 
the hemoglobin levels dropped from 11 g% to 9 g%. 
 
Outcomes  For dichotomous data 2x2 table for each intervention. 
 
Success rate 
 Yes No 
PGF2α 10 0 
Oxytocin 6 5 
 
Success rate 
 Yes No 
PGF2α 10 0 
Salin 
solution 
0 7 
 
 
 
 Complications 
 
Fever 
 Yes No 
PGF2α 1 9 
Oxytocin 1 10 
 
Bibliografía 55
 
Fever 
 Yes No 
PGF2α 1 9 
Saline 
solution 
0 7 
 
Fever   
 Yes No 
PGF2α 1 9 
Manual 
removal 
2 7 
 
 
Abdominal Pain 
 Yes No 
PGF2α 3 7 
Oxytocin 1 10 
 
Abdominal Pain  
 Yes No 
PGF2α 3 7 
Saline 
solution 
0 7 
 
Abdominal Pain 
 Yes No 
PGF2α 3 7 
Manual 
removal 
2 7 
 
 
 
For continuous data mean, Sd, Se. 
 
Explusion time (min)  Mean and SE 
PGF2α   7min +/- 1 
Oxytocin 13 min +/- 1 
Saline solution: None in 30 minutes. 
 
Blood loss (ml) Mean and SE 
PGF2α  210ml +/- 40 
Oxytocin 229ml +/- 39 
Saline solution 231ml +/- 31 
Manual removal 237ml +/- 39 
 
Author conclutions 
and comments 
“…we propose that the use of 20 mg PGF2α injection diluted in 20ml saline 
solution could be a mode of treatment before deciding on manual placental 
removal…” Authors suggest that intraumbilical vein injection of PGF2 might 
be a beneficial, non-surgical method for treating retained plaenta. Authors 
propose that the use of 20 mg PGF2 injection diluted in 20 mL saline solution 
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could be a mode of treatment before deciding on maual placental removal. 
The injection mode of PGF2 has negligible side effects and apart form a 
possible allergic reaction, no other precautions need to be taken. Oxytocin 
might reduce the incidence of manual lysis of the placenta and achieve partial 
success. 
Our comments High risk of bias. Low quality of the study. Suggest a benefit of PGF2 
injected in the umbilical vein. NNT Calculated for success with PGF2 vs 
oxytocin: 2.24. The suty reported mean and standard error for continuos data. 
We had to make standad desviation imputation. 
 
Correspondence 
requiered 
No. 
 
 
Risk of bias  BIDER 
Item    Authors’ judgement Description 
Adequate sequence 
generation?  
Low Risk “…We studied all the patients prospectively and 
by computerized randomization..." Comment: 
probably done. 
Allocation 
concealment?  
High Risk One group (manual removal of placenta) included 
three patients assigned because of their 
excessive bleeding without any random process. 
Blinding?  
(Retained Placenta) 
Low Risk Outcome: Expulsion of the placenta without 
manual removal.  
They did not describe the masking procedure 
between the arms of the trial, but the review 
authors judge that the outcome measurement are 
not likely to be influenced by lack of blinding. 
Objective outcome. Comment: low risk of bias. 
 
Blinding? (Subjective 
outcomes) 
High Risk Outcomes: Estimated Blood Loss, Painful 
Contractions, Fever or sickness or vomiting or 
diarrhea or dizziness or flushes. 
They did not describe the masking procedure 
between the arms of the trial blinding. Subjective 
outcome. Comment: probably no blinding or 
incomplete blinding, and the  outcome  
measurement is likely  to be influenced by lack of 
blinding. 
 
Blinding? (Objective 
Outcomes) 
High Risk Outcomes: Maternal Transfusion, Duration of third 
stage of labour, Time for delivery of the placenta. 
They did not describe the masking procedure 
between the arms of the trial blinding. Objective 
outcome. Comment: probably no blinding or 
incomplete blinding, and the  outcome  
measurement is likely  to be influenced by lack of 
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blinding. 
 
Incomplete outcome 
data addressed? 
(Short-term outcomes 
(1 hour)) 
 
 
Unclear Risk Outcomes: Expulsion of the placenta without 
manual removal, Estimated blood loss, Duration 
of third stage of labour, Time for delivery of the 
placenta. 
Did not mentioned the number of withdrawals and 
follow-up lost and none explanation about the 
reasons was provided. 
Incomplete outcome 
data addressed? 
(Medium-term 
outcomes (1 to 96 
hours) 
Unclear Risk Outcomes: Maternal transfusion, Painful 
contractions, Fever or sickness or vomiting or 
diarrhea or dizziness or flushes. 
Did not mentioned the number of withdrawals and 
follow-up lost and none explanation about the 
reasons was provided. 
 
Free of selective 
reporting?  
Unclear Risk The study protocol is not available and is unclear 
that the published reports included all expected 
outcomes, including those that were pre-specified. 
The report do not has insufficient information to 
permit judgment of “Yes” or “No”. 
Free of other bias?  Low Risk Appear to be free of other sources of bias. 
 
 
Characteristics of included studies [Heleen 2006]. 
Methods • Location of the study: 6 hospitals in The Netherlands. 
 
• Trial design: Randomized clinical trial, parallel, two arms. First phase from 
July 2002 to September 2003. The study had a sequential design in which the 
first-phase Sulprostone was compared with placebo. If interim analysis would 
show sulprostone to be superior to placebo, the placebo arm would be 
discontinued in the second phase of the study. 
 
Second phase: From September 2003 until August 2004. 
 
• Power calculation performed: A truncated sequential probability ratio test, 
according to Whitehead, was used to include a maximum of 100 patients. 
Interim analysis were performed after each 5 consecutive patients. The 
procedure was designed to have a power of 80% to detect a 25% difference 
in success rate of expulsion of the placenta between the placebo group (10%) 
and the sulprostone group(35%; α =0.05). If an interim analysis were to 
indicate the superiority of sulprostone, the remaining patients would all 
receive sulprostone to gather more in formation on efficacy and safety. 
 
• Method used to generate random allocation: first phase “…Study medication 
was randomized in blocks of 4…”  
 
• Methods used to maintain allocation concealment: first phase “…the 
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allocation of sealed envelopes was in the sequence of enrolment…” 
 
• Number of women enrolled, randomised, excluded after randomisation, and 
analysed: First phase: 60 patients with retained placenta were asked to 
participate in the first phase of the study. One patient refused to participate. 
Fifty-nine patients gave their informed consent and were randomised. Nine 
patients were excluded after randomization and the remaining 50 patients 
were available for analysis, 24 patients were allocated to the sulprostone 
group, and 26 patients were allocated to the placebo group. 
 
Second phase:  
55 patients were eligible to participate in the second phase of the study. Fifty-
three patients received sulprostone; 2 patients did not receive trial medication 
(1 patient because she withdrew her consent, and 1 patient because of 
technical failure of the sulprostone infusion pump). 53 patients were included. 
 
• Use of any method of blinding of the researchers to the intervention in order 
to evaluate outcomes: first phase “…The physician in charge was blinded to 
the trial medication…” Comment: Unclear.  In the second phase of the study, 
the blinding was discontinued, and all the patients received 250 mcg 
sulprostone in 30 minutes.  
 
 
The primary outcome variable was the presence or absence of manual 
removal of placenta. Unclear, objective outcome Comment: low risk of bias. 
 
The secondary outcome variable was the amount of blood loss (ml): 
Subjectively estimated in referred women after home delivery. Comment: 
unclear risk of bias. Objectively estimated during hospital delivery. Comment: 
unclear method. Unclear risk of bias.  
 
Minor complications (Flushes, nausea, dizziness, painful contractions): 
Unclear, probably subjectively estimated. Comment: Unclear risk of bias. 
 
Others interventions (nitroglycerine or isoflurane): Unclear, Subjectively 
estimated. Comment: Unclear risk of bias. 
 
 
• Number of participants lost to follow up in the two groups. Nine patients after 
randomization. Did not mention group’s distribution or causes. None after 
intervention administration. Two before patients and none in second phase 
after intervention administration. 
 
• Use of intention-to-treat analysis: “The set of patients that was analyzed 
consisted of subjects who were assigned randomly and who had been started 
on trial medication…”   
 
“…Nine patients could not be included: One patient withdrew her consent; 1 
patient 
Mentioned after inclusion that she had a cardiac condition that was a 
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contraindication to participate in the study; in 3 patients, the placenta was 
expelled within 60 minutes after delivery of the infant before trial medication, 
and in 4 patients, blood loss exceeded 1000mL before medication…”  
 
“… We analyzed the condition of patients in phase I who had both been 
assigned randomly and who had actually started with trial medication, instead 
of after randomization alone. We therefore did not include in the analysis of 
the first phase of the study 9 patients who had been assigned randomly but 
had not actually received trial medication…”  “…we analyzed only those 
patients who had both been assigned randomly and who had actually 
received the trial medication…” 
 
Comment: probably not done. 
 
• Funding sources, reported: No. 
 
• Ethical issues (use of signed informed consent and ethics approval): The 
study had been approved by the institutional review board of the Radboud 
University Nijmegen Medical Centre. 
 
Participants • Inclusion and exclusion criteria defined.  
 
Exclusion criteria: 
Current status:  
Blood loss ≥ 1000mL 
Reduction in diastolic blood pressure ≥20mmHg 
Tachycardia ≥120beat/min 
Gynecologic infection 
General history 
Age < 18 or > 40 years 
Gestational age ≥ 28wk 
Asthma, bronchitis 
Epilepsy 
Cardiac disease 
Hypertension, preeclampsia, HELLP(hemolysis, elevated liver enzymes, and 
low platelet count) syndrome 
Liver failure, renal failure 
Stomach ulcer, ulcerative colitis 
Sickle cell anemia, b-thalassemia 
Glaucoma 
 
• Setting: Study participants were recruited from patients who were admitted 
for hospital delivery and from patients who had been referred because of 
retained placenta after home delivery. 
 
• Baseline information on the participants in order to have comparable 
intervention and control groups at entry (eligibility criteria, management of the 
third stage of labour, retained placenta definition, exclusion of patients with a 
clear diagnosis of  placenta accreta).  
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“…Patients who were delivered in the hospital received all active 
management of labor; immediately after the delivery of the infant, oxytocin 10 
IU was administered intramuscularly, and controlled cord traction was 
performed at the first uterine contraction…” 
 
“…Patients who were referred because of Retained placenta after home 
delivery received the same treatment after they had arrived in the hospital…” 
 
“…The administration of study medication started 60 minutes after the 
delivery of the Infant…” 
 
 
Population first phase: Total 50 women. 
Nulliparous women 25 and 25 multiparas women 
Vacuum extraction 17 women. (6 first phase 11 second phase) 
History of Manual removal of placenta 23 women. 
History of Cesarean delivery 11 women. 
History of Curettage 25 women. 
 
Population second phase: Total 53 women 
Nulliparous women 37 and 16 multiparas women 
Vacuum extraction 11 women. 
History of Manual removal of placenta 1 women. 
History of Cesarean delivery 1 women. 
History of Curettage 8 women. 
 
Table II shows obstetrics histories, but not all baseline information of the 
patients. 
 
Interventions • Total number of intervention groups: Two groups. 
 
• Types of interventions:  Prostaglandins types, doses, route of administration 
a duration intervention.  
 
Intervention: Sulprostone (synthetic prostaglandin-E2 derivative) 250 mg by 
30minutes of intravenous infusion. 
Control: placebo by 30minutes of intravenous infusion. 
 
In the second phase of the study, the blinding was discontinued, and all 
patients received 250 mg sulprostone in 30minutes. 
 
•Adherence to planed intervention and Other interventions in the groups 
under evaluation.  
 
“…If the placenta could not be expelled, the bladder was catheterized, and 30 
minutes later controlled cord traction was reattempted. In case the placenta 
was retained at 45 minutes after delivery of the infant, the patient was asked 
to participate in the trial...” 
 
“…During the 30 minutes of administration of medication, controlled cord 
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traction was performed once every 10 minutes…” 
 
“…If the placenta had not been expelled after the full dose of trial medication 
had been given or if blood loss had exceeded 1500mL during the 
administration of the trial medication, manual removal of placenta was 
performed…” 
Outcomes  • Outcomes stated in methods versus outcomes reported in results: Yes. The 
primary outcome variable was the presence or the absense or MRP. If the 
placenta had not been expelled after the full dose of trial medication had been 
given or if blood loss had exceeded 1500 mL, during the administration of the 
trial medication, MRP was performed. 
 
• How secondary Outcomes such as:   postpartum haemorrhage, severe 
postpartum haemorrhage, hypovolemic shock, acute renal insufficiency, 
duration of third stage of labour,  time for delivery of the placenta, maternal 
satisfaction with treatment and cost-effectiveness of intervention were defined 
The primary outcome variable was the presence or absence of manual 
removal of placenta 
The secondary outcome variable was the amount of blood loss (ml) 
 
• Differences between groups for outcome assessment in terms of method 
used to clinically or subjectively estimated blood loss: 
  The amount of in-hospital blood loss was determined by weight; blood loss 
before entering the hospital was estimated by the referring midwife. 
 
• Time of follow up of participants to measure outcomes: maternal mortality, 
maternal transfusion, expulsion of the placenta without manual removal, 
hysterectomy or others surgical procedures, endometritis, major puerperal 
infection,  puerperal infection, maternal admission to intensive care unit, 
haemoglobin or hematocrit levels, maternal length of hospital stay: Short, only 
inmediate outcomes.   
 
• How adverse event reports (painful contractions, fever,  sickness,  vomiting, 
diarrhea, dizziness, flushes, serious maternal side effects of therapy, 
hypotension, hypertension, coronary spasms or bronchospasm) were 
meassured: 
 
Adverse events were recorded. Serious adverse side effects were not 
observed in the phase 1 of the study. Reported minor side effects included 
painful contractions (sulprostone group 3, placebo group 2), dizziness (one in 
each group), flushes (placebo group 1), and nausea (placebo group 1). One 
patient in each group required a uterine relaxant during MRP. 
 
In phase 2: none of the patients in the expulsion group received a blood 
transfusion, in contrast to 10 in the MRP group. No serious effects were 
observed. Minor side effets included abdominal cramp in 8 patients, nausea in 
3, and shiverinf in 2 patients. None of the patients required a uterine relaxand 
during MRP. 
 
None of the patients needed hysterectomy. 
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Outcomes  For dichotomous data 2x2 table for each intervention. 
First phase 
Expelled  Placenta   
 Yes No 
PG 13 11 
Placebo 4 22 
 
The difference was significant (P =.034, final analysis), the (bias adjusted) 
estimate of the success rate was 52% (approximate95% CI,42%-62%). 
 
Second phase: Expelled placenta 25/53  Manual removal 28/53 
First and second phase 
Expelled  Placenta  
 Yes No 
PG 38 9 
Placebo 4 22 
 
 
Blood Transfusion 
First phase 
 Yes No 
PG 6 18 
Placebo 8 18 
 
Second phase: None of the patients in the expulsion group received a blood 
transfusion, in contrast to 10 patients in theMRP group. 
 
Blood transfusion was needed in 16 patients (21%) in the Sulprostone group 
and in 8 patients (31%) in the placebo group (no significant difference, P 
=0.30) 
First and second phase 
Transfusion  
 Yes No 
PG 16 61 
Placebo 8 18 
 
Minor side effects 
First phase 
Painful contraction  
 Yes No 
PG 3 21 
Placebo 2 24 
 
Dizzines  
 Yes No 
PGF 1 23 
Placebo 1 25 
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Flushes  
 Yes No 
PGF 0 24 
Placebo 1 25 
 
Nausea   
 Yes No 
PGF 0 24 
Placebo 1 25 
 
Other interventions (uterine relaxant nitroglycerine or isoflurane) 
 
First phase 
Other intervention   
 
 Yes No 
PG 1 23 
Placebo 1 25 
 
Second phase: In sulprostone group minor side effects included abdominal 
cramps in 8 patients, nausea in 3 patients, and shivering in 2 patients. None 
of the patients required a uterine relaxant during MRP. 
 
For continuous data mean, Sd, Se. 
First phase 
Sulprostone Blood loss (ml) Mean and SD 
Manual removal 1152 +/- 637 (n=11) 
Expelled placenta  687 +/- 400 (n=13) 
Total sulprostone 901 +/- 550(n=24) Range (110-2300) 
 
Placebo Blood loss (ml) Mean and SD 
Manual removal 1511 +/-  725(n=22)  
Expelled placenta  1114 +/-  387(n=4) 
Total Placebo 1450 +/- 693(n=26) Range (570-3000) 
 
Blood loss was significantly less in the sulprostone group than in the placebo 
group, with mean values of 901mL and 1450mL (P=.004,Student t 
test),respectively. 
 
In women without MRP, average blood loss between women in the 
sulprostone group (687 +/- 400mL) and the placebo group (1114 +/- 387mL) 
was not significantly different (P=.12). The same was true for women with 
MRP; average blood loss in the sulprostone group (1152 +/- 637mL) was not 
significantly different from that in the placebo group (1511 +/- 725mL; P =.17). 
 
Second phase:  
Manual removal 1453 +/- 635 (n=28) 
Expelled placenta 814 +/- 309 (n=25) 
Total sulprostone 1140 +/- 600 (n=53) Range (250-2500) 
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Blood loss was significantly less in the expulsion group (814 +/- 309mL) as 
compared with the MRP group (1453 +/- 635mL; P < .001, Student t test). 
First and second phase: 
Manual removal 1368 +/- 636 (n=39) 
Expelled placenta 770 +/- 342 (n=38) 
Total sulprostone 1062 +/- 596 (n=77) 
Average blood loss in the sulprostone group (1062 +/- 596mL) was less than 
in the placebo group (1450 +/- 693mL; P =0.03 Student t test). 
Author conclutions 
and comments 
Authors concluded that in women with RP, the intravenous administration of 
250 mg sulprostone in 30 minutes reduces the need for MRP by 49%. The 
administration of sulprostone reduced the amount of blood loss. Because 
blood loss in patients who needed MRP was markedly higher than in those 
who did not need MRP, the data suggest that reduction in blood loss is not a 
direct effect of sulprostone but rather an indirect effect caused by avoidance 
of MRP. 
Our comments NNT reported: no. Calculated for phase one: 2.6 with sulprostone to avoid an 
aditional MRP.   
The following factors may affect the quality of the study: How many patients 
were in-hospital and how many were referred could influence the stimation of 
blood loss; not all the baseline date of the treatment groups were compared, 
and analysis by treatment received, noy by intention-to-treat. Second phase 
not blinded, may have an effect on the results. Quality of the study: medium. 
Intervention with clinical impact. 
Correspondence 
requiered 
No. 
 
Risk of bias  Heleen 
Item    Authors’ judgement Description 
Adequate sequence 
generation?  
Low Risk  “…Study medication was randomized in blocks of 
4…” Comment: probably done. 
Allocation 
concealment?  
Low Risk “…the allocation of sealed envelopes was in the 
sequence of enrolment…” Comment: probably 
done. 
Blinding?  
(Retained Placenta)  
Low Risk Outcome: Expulsion of the placenta without 
manual removal. 
"...the physician in charge was blinded to the trial 
medication..." they did not describe how 
implemented the masking procedure between the 
arms of the trial, but the review authors judge that 
the outcome measurement are not likely to be 
influenced by lack of blinding. Objective outcome. 
Comment: low risk of bias 
  
Blinding? 
(Subjective 
outcomes) 
High Risk Outcome: Flushes, nausea, dizziness, painful 
contractions. 
They did not describe the masking procedure for 
patients between the arms of the trial blinding. 
Subjective outcome. Comment: probably no 
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blinding or incomplete blinding, and the  outcome  
measurement is likely  to be influenced by lack of 
blinding. 
 
Blinding? (Objective 
Outcomes) 
Unclear Risk Outcome: Blood loss (ml), 
"...the physician in charge was blinded to the trial 
medication..." they did not describe how 
implemented the masking procedure between the 
arms of the trial. Blood loss subjectively estimated 
in referred women after home delivery and 
objectively estimated during hospital delivery. 
Comment: unclear method. Unclear risk of bias. 
 
Incomplete outcome 
data addressed?  
(Short-term 
outcomes (1 hour)) 
 
High Risk They did a “As-treated” analysis because they 
only included the results from those patients who 
had both been assigned randomly and who had 
actually received the trial medication. 
Incomplete outcome 
data addressed? 
(Medium-term 
outcomes (1 to 96 
hours) 
High Risk They did a “As-treated” analysis because they 
only included the results from those patients who 
had both been assigned randomly and who had 
actually received the trial medication. 
Free of selective 
reporting?  
Unclear Risk The study protocol is not available and is unclear 
that the published reports included all expected 
outcomes, including those that were pre-specified. 
The report do not has insufficient information to 
permit judgment of “Yes” or “No”. 
Free of other bias?  High Risk Trial stopped early due to apparent benefit. 
Characteristics of included studies [Rogers 2007]  
Methods • Location of the study: Performed from 2004 to 2005 in two Hong Kong 
obstetric units, Prince Wales Hospital (NT) and Princes Margaret Hospital 
(Kowloon), Hong Kong. 
 
• Trial design. Randomized controlled trial parallel three arms. 
 
“…the triangular test for the comparison between Group1 (control) and Group 
2 (Syntocinon). The lower border of the triangle was crossed after 36 cases 
(12 in each of the 3 groups), indicating that a significant result in favor of 
either the control or Syntocinon group would be unlikely to be found within the 
projected maximum sample size and activating the automatic stopping rule. 
This arm of the trial was therefore terminated and the trial continued with only 
two arms. All subsequent cases recruited were allocated to receive either 
Syntocinon or misoprostol with an eventual allocation ratio of approximately 
1:2:2 (saline control: oxytocin: misoprostol)…”  “…that after a total of 54 cases 
a significant reduction in MROP was observed in the misoprostol group, 
triggering the automatic stopping rule and terminating the trial...” 
 
• Power calculation performed: “…Group sequential analysis (the triangular 
test) was used for statistical analysis on an intention-to-treat basis. The 
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sequential model was based on expected rates of spontaneous placental 
delivery of 20%, 50%, and 80% in control, Syntocinon, and misoprostol 
groups respectively. Simulation using an effect size (log odds ratio) of 1.5 and 
p< 0.05 suggested an absolute maximum sample size of 216 (72 in each 
arm)…”  
 
Authors mention that a group sequential research model (triangular test: 
PEST4) was adopted to minimize the sample size because of the low 
frequence of retained placenta. As this analysis indicated that a significant 
result in favor of either the control or Syntocinon group would be unlikely to be 
found within the projected maximun sample size, the automatic stopping rule 
was activated. 
 
• Method used to generate random allocation: “…according to a table of 
computer-generated random numbers…”  
 
• Methods used to maintain allocation concealment:  
“...The syringes were packed and coded according to a table of computer-
generated random numbers…” 
 
“…One pre-prepared syringe (with randomly allocated solution) was obtained 
from the refrigerator of the delivery suite and the syringe number noted on the 
research form...” 
 
“…they were enrolled by opening the next in a series of randomized treatment 
packs…” 
 
 
• Number of women enrolled, randomised, excluded after randomisation, and 
analysed. 
  
“…In total, 87 cases were identified with a prolonged third stage of labor 
(>30min), of which 33 were not recruited….”  
 
“…Of the remaining 54 cases who were randomized, cannulation of the 
umbilical vein failed in 3 cases, one from each group…” 
 
“…Allocated to Syntocinon group (n=20). Received Syntocinon (n=19) and 
Failed catheterization (n=1). Analysed (n=20)…” 
 
“…Allocated to N-saline control group (n=13).  Failed catheterization (n=1) 
and analysed (n=13)…” 
 
“…Allocated to misoprostol group (n=21). Received misoprostol (n=20) and 
failed catheterization (n=1). Analysed (n=21)…” 
  
• Use of any method of blinding of the researchers to the intervention in order 
to evaluate outcomes.   
 
“…The midwifery and medical staff could not be entirely blinded as to which 
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were controls and which contained active drug, as misoprostol, although 
readily soluble in saline, produces a milky suspension, where as saline and 
Syntocinon are clear solutions…” 
 
The primary outcome variable was the presence or absence of manual 
removal of placenta. Objective outcome Comment: low risk of bias. 
 
The secondary outcome variable was the duration of third stage in minutes. 
Objective outcome Comment: low risk of bias. 
 
• Number of participants lost to follow up in the three groups. One in each 
group.  
• Use of intention-to-treat analysis: Yes.  
• Funding sources, reported: No.  
• Ethical issues (use of signed informed consent and ethics approval): The 
study protocol was approved by the Clinical Research Ethics Committee of 
the Chinese University of Hong Kong and written consent was obtained.  
 
Participants • Inclusion and exclusion criteria defined.  
“…All women having singleton pregnancy beyond 37 weeks of gestation and 
prolongation of the third stage of labor (>30min) following vaginal delivery 
were eligible to participate in the study unless there was significant 
bleeding…” 
 
In table I the authors mention the number of patient excluded, reasons for 
exclusions and outcomes of these women. 
• Setting: In-patients. 
 
• Baseline information on the participants in order to have comparable 
intervention and control groups at entry (eligibility criteria, management of the 
third stage of labour, retained placenta definition, exclusion of patients with a 
clear diagnosis of  placenta accreta):  
 
“…In both units, the third stage of labor is managed by giving prophylactic 
oxytocics (syntometrine1ml intramuscularly or Syntocinon 10 units 
intravenously) at delivery of the anterior shoulder, followed by early clamping 
of the umbilical cord…” 
 
“…If spontaneous placental delivery had not occurred 45 min after the birth of 
the baby, they were enrolled by opening the next in a series of randomized 
treatment packs…” 
 
“…Pipingas procedure: 
One pre-prepared syringe (with randomly allocated solution) was obtained 
from the refrigerator of the delivery suite and the syringe number noted on the 
research form. 
A size 10 nasogastric suction catheter was inserted along the umbilical vein. If 
resistance was felt, the catheter was retracted by1-2cm and then advanced 
further if possible. If the catheter could not be advanced further without force, 
injection of solution was performed from this position. If the majority of the 
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catheter had been inserted when resistance was felt, indicating it had reached 
the placenta, it was retracted by 3-4 cm to ensure the tip was in the umbilical 
vein and not in a placental branch. 
If spontaneous placental separation/delivery had not occurred within 45min 
after delivery of the baby, the prepared solution was injected through the 
catheter, then the umbilical cord was clamped with the catheter in situ. The 
time of injection was noted…” 
 
“…If placental delivery failed to occur within 30 min of the injection, or 
significant bleeding occurred, MROP was performed. The time and mode of 
placental delivery (spontaneous/MROP) was noted…” 
 
Authors mention that there were no significant differences between groups en 
terms of age, parity, duration of second stage, or duration of third stage prior 
to intervention. 
Interventions • Total number of intervention groups: Three groups. 
 
• Types of interventions:  Prostaglandins types, doses, route of administration 
a duration intervention.  
 
1. Syntocinon 50 IU in 30 ml normal saline, 
2. Misoprostol 800mcg dissolved in 30ml normal saline 
3. 30 ml normal saline only. 
 
“…Cannulation of the umbilical vein was then attempted and, if the placenta 
remained adherent (no bleeding) and cannulation was successful, 
intraumbilical injection was performed...” 
 
•Adherence to planed intervention and Other interventions in the groups 
under evaluation.  
 
“…The solutions were prepared under aseptic conditions by a research 
assistant every 3 days in each unit. Solutions not used within this time period 
were discarded and replaced...” 
 
Outcomes  • Outcomes stated in methods versus outcomes reported in results: Principal 
outcomes (manual removal of the placenta and time) stated in methods. 
 
• How secondary Outcomes such as:   postpartum haemorrhage, severe 
postpartum haemorrhage, hypovolemic shock, acute renal insufficiency, 
duration of third stage of labour,  time for delivery of the placenta, maternal 
satisfaction with treatment and cost-effectiveness of intervention were defined 
 
The primary outcome variable was the presence or absence of manual 
removal of placenta. 
 
The secondary outcome variable was the duration of third stage in minutes. 
 
• Differences between groups for outcome assessment in terms of method 
used to clinically or subjectively estimated blood loss: No. 
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• Time of follow up of participants to measure outcomes: maternal mortality, 
maternal transfusion, expulsion of the placenta without manual removal, 
hysterectomy or others surgical procedures, endometritis, major puerperal 
infection,  puerperal infection, maternal admission to intensive care unit, 
haemoglobin or hematocrit levels, maternal length of hospital stay: Not clear. 
It seams short. Authors mentioned only 30 min after the intervention or the 
presence of significant bleeding to practice a manual removal of the placenta. 
    
 
• How adverse event reports (painful contractions, fever, sickness,  vomiting, 
diarrhea, dizziness, flushes, serious maternal side effects of therapy, 
hypotension, hypertension, coronary spasms or bronchospasm) were 
meassured: adverse event reports not mentioned. 
 
Outcomes  For dichotomous data 2x2 table for each intervention. 
 
Expelled  Placenta 
 Yes No 
PG 12 9 
Oxytocin 4 16 
 
 
Expelled  Placenta  
 Yes No 
PG 12 9 
Placebo 6 7 
 
“…The misoprostol group had significantly fewer cases of MROP (9/21 versus 
23/33 x2=4; p<0.05). The odds ratio for MROP without misoprostol compared 
to with misoprostol was OR 3.1 (95%CI=1-9.5)…”  “…amongst the Syntocinon 
group alone was OR 5.3 (95%CI:1.3-21.5) compared to those who received 
misoprostol...” 
 
For continuous data mean, Sd, Se. 
 
Misoprostol Duration of third stage(min) Mean and SD 
Manual removal 113.3 +/- 17.8 (n=9) 
Expelled placenta  83.9+/- 25.9 (n=12) 
Total Misoprostol 96.5 +/- 26.8 (n=21)  
 
Oxytocin Duration of third stage(min) Mean and SD 
Manual removal 99.8 +/-  20.5 (n=16)  
Expelled placenta  67.7 +/-  22.0(n=4) 
Total Oxytocin 92.5 +/- 24.8 (n=20)  
 
Placebo Duration of third stage(min) Mean and SD 
Manual removal 139.8 +/- 65.1(n=7)  
Expelled placenta  79.3+/-  13.4(n=6) 
Total Placebo 111.8 +/- 56.3(n=13) 
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Author conclutions 
and comments 
Misoprostol (800 mcg) dissolved in 30 mL normal saline and administered by 
intraumbilical injection using the Pipingas technique significantly reduces the 
need for manual removal for retained adherent placenta, whereas Syntocinon 
has similar effectiveness to injection of normal saline alone.  
 
Our comments NNT reported: No. (Calculated: ARR: 0.24, NNT=4.1) 
Correspondence 
requiered 
The following aspects affect the quality of the study: low precision of the 
estimatives secondary to low power (difference between the calculated 
sample size and the analized), short follow up, and abscence of report of 
adverse events. Not blinding. Quality of the study: medium. Intervention with 
clinical impact. 
 
 
Risk of bias   ROGERS 
Item    Authors’ judgement Description 
Adequate sequence 
generation?  
Low Risk “...according to a table of computer-
generated random numbers…” 
Allocation concealment?  Low Risk “...The syringes were packed and coded 
according to a table of computer-generated 
random numbers…” Comment: probably 
done. 
Blinding? (Retained 
Placenta)  
Low Risk Outcome: Expulsion of the placenta without 
manual removal. 
They mention that masking procedure 
between the arms of the trial was impossible 
because the appearance of the intervention: 
“…The midwifery and medical staff could not 
be entirely blinded as to which were controls 
and which contained active drug, as 
misoprostol, although readily soluble in 
saline, produces a milky suspension, where 
as saline and Syntocinon are clear 
solutions…” The review authors judge that 
the outcome measurement are not likely to 
be influenced by lack of blinding. Objective 
outcome. Comment: low risk of bias 
 
Blinding? (Subjective 
outcomes) 
Unclear Risk This trial did not include subjective outcome. 
 
Blinding? (Objective 
outcomes) 
Low Risk Outcome: Duration of third stage in minutes. 
They mention that masking procedure 
between the arms of the trial was impossible 
because the appearance of the intervention: 
“…The midwifery and medical staff could not 
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be entirely blinded as to which were controls 
and which contained active drug, as 
misoprostol, although readily soluble in 
saline, produces a milky suspension, where 
as saline and Syntocinon are clear 
solutions…” The review authors judge that 
the outcome measurement are not likely to 
be influenced by lack of blinding. Objective 
outcome Comment: low risk of bias. 
 
Incomplete outcome data 
addressed?  
(Short-term outcomes (1 
hour)) 
Low Risk Were not withdrawals or loss of participants 
to follow up between groups, so the 
likelihood of attrition bias is very low. 
Incomplete outcome data 
addressed?  
(Medium-term outcomes (1 
to 96 hours) 
Low Risk Were not withdrawals or loss of participants 
to follow up between groups, so the 
likelihood of attrition bias is very low. 
Free of selective reporting?  Unclear Risk The study protocol is not available and is 
unclear that the published reports included 
all expected outcomes, including those that 
were pre-specified. The report do not has 
insufficient information to permit judgment of 
“Yes” or “No”. 
Free of other bias?  High Risk Trial stopped early due to apparent benefit. 
 
Characteristics of Excluded Studies [ordered by year of study] 
Characteristics of excluded studies [ordered by study ID]  
Study  Reason for exclusión 
Nardin 2011 Non clinical trial. Systematic review. Other Intervention. 
N. Rizwan 2010 Prospective and retrospective study. 
S.  Sundaram 2009  Retrospective study. 
WHO 2009  Non clinical trial. Guideline. 
Habek 2007 Non-randomized prospective study. 
G. Radhakrishnan 2007 Non clinical trial. Letter to editor. 
G. van Stralen 2007  Non clinical trial. Letter to editor. 
M. Rogers 2007  Non clinical trial. Letter to editor. 
PocketMedicine 2006 Non clinical trial. Narrative review. 
A. Weeks 2005  Randomized clinical trial. Different intervention.  
P. Ranka 2003 Non clinical trial. Case report. 
S.R Chatterjee 2002 Non clinical trial. Cases report. 
G. Carroli 2001  Non clinical trial. Systematic review. Other Intervention. 
Yiu-Tai Li 2001  Non-randomized prospective study.  
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Characteristics of Ongoing Studies [ordered by year of study] 
Characteristics of ongoing studies [ISRCTN45330307]  
Trial name or title  Misoprostol in the management of retained placenta - a safe 
alternative for manual removal? A randomised controlled trial.  
Methods Multicentre, randomised, double-blinded, placebo controlled, 
parallel group trial.  
Participants   Participants – inclusion criteria  
1. All women with at least 25 completed pregnancy weeks and 
retained placenta  
2. At least 18 years of age  
3. Master the Dutch language in word and script 
 
Participants - exclusion criteria  
1. Excessive blood loss (greater than 1000 ml) within 60 minutes 
after the delivery of the newborn  
2. Allergy for misoprostol or one of its components  
 
Interventions  All women with retained placenta after vaginal birth will be 
included in our study. In the case of a retained placenta, 
administration of either 800 mcg of misoprostol or placebo 60 
minutes after birth of the baby will be performed, in absence of 
postpartum haemorrhage. If a final attempt to deliver the placenta 
by controlled cord traction after 45 minutes fails, manual removal 
of the placenta will be performed. Side effects will be registered.  
 
Outcomes  
 
Primary outcome measure(s)  
1. Number of spontaneous delivered placentas  
2. Number of manual removals and amount of blood loss  
 
Secondary outcome measure(s)  
1. Interval between delivery of the baby and administration of 
misoprostol  
2. Interval between administration of misoprostol and delivery of 
the placenta  
3. Placenta captiva  
 
Starting date Anticipated start date  
01/08/2007  
Contact information Dr  Giel  van Stralen  
Leiden University Medical Centre (LUMC) Department of 
Gynaecology Leiden 2300 RC Netherlands. Email 
G.van_Stralen@lumc.nl.  
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Characteristics of ongoing studies [ISRCTN16104753]  
Trial name or title  Treatment of a retained placenta with misoprostol, a double-blind 
randomised controlled trial in Tanzania.  
Methods Double-blind randomised controlled trial. 
Participants   Participants - inclusion criteria  
Women with a retained placenta 30 minutes after delivery of the 
newborn (and a pregnancy duration of at least 28 weeks [birth 
weight 1 kg]). All women will receive active management of third 
stage of labour before inclusion.  
Participants - exclusion criteria  
1. Blood loss greater than 750 ml 30 minutes after delivery  
2. Pulse rate greater than 120 beats/minute  
3. Blood pressure (BP) dropped greater than 20 mmHg diastolic 
compared with BP before delivery  
4. Anaemia (haemoglobin [Hb] less than 100g/dl). Measurement 
of third trimester of pregnancy or around delivery. 
 
Interventions  Study medication will be randomised in blocks and the allocation 
of sealed envelopes will be in sequence of enrolment. 
Randomisation of misoprostol to placebo will be 2:1. 30 minutes 
after delivery of the baby the women will receive study medication 
sublingually: either misoprostol 800 microgram or placebo.  
 
Duration of follow up: until discharge next day if no complications 
occur. At discharge patient will be counselled that they have to 
come back in case of complications (blood loss and/or fever).  
Outcomes  
 
Primary outcome measure(s)  
Reduction in the amount of manual removal of placenta (under 
anaesthesia) 60 minutes after delivery of the baby.  
 
Secondary outcome measure(s)  
1. Blood loss  
2. Need for blood transfusion  
 
Hb will be checked the morning after the manual removal or the 
sponteneous expulsion of the placenta. After this it will be 
decided if a blood transfusion is necessary.  
Starting date Anticipated start date  
04/04/2008 
Contact information Dr  Heleen  van Beekhuizen  
Department of Obstetrics and Gynaecology. Erasmus Medical 
Centre. 3000 CA Rotterdam, The Netherlands. 
 
  
 
 
Appendices 
Appendix 1. Searches Estrategies  
 
Pudmed database 
Search Date: 31/05/2011  
 
 
Searc
h 
Most Recent Queries Result 
#43 Search #1 AND #9 AND #40 1688 
#42 Search (("prostaglandins"[MeSH Terms] OR "prostaglandins"[tw] OR 
"prostanoids"[tw] OR "prostaglandins"[All Fields]) OR ("dinoprostone"[MeSH 
Terms] OR "dinoprostone"[All Fields] OR "dinoprostone"[tw] OR "PGE2 
alpha"[tw] OR "alpha, PGE2"[tw] OR "PGE2alpha"[tw] OR "Prostaglandin E2 
alpha"[tw] OR "alpha, Prostaglandin E2"[tw] OR "Prostaglandin E2alpha"[tw] OR 
"PGE2"[tw] OR "Prostaglandin E2"[tw] OR "E2, Prostaglandin"[tw] OR "Prepidil 
Gel"[tw] OR "Prostenon"[tw]) OR ("prostaglandin F1"[Supplementary Concept] 
OR "prostaglandin F1"[All Fields] OR "prostaglandin F1"[tw] OR "PGF1"[tw] OR 
"prostaglandin F1alpha"[tw] OR "PGF1alpha"[tw] OR "PGF1 alpha"[tw]) OR 
("prostaglandin E2 methyl ester"[Supplementary Concept] OR "prostaglandin E2 
methyl ester"[All Fields] OR "prostaglandin E2 methyl ester"[tw] OR "PGE2 
methyl ester"[tw]) OR ("dinoprost"[MeSH Terms] OR "dinoprost"[All Fields] OR 
"dinoprost"[tw] OR "PGF2"[tw] OR "Prostaglandin F2alpha"[tw] OR "F2alpha, 
Prostaglandin"[tw] OR "PGF2alpha"[tw] OR "Prostaglandin F2"[tw] OR 
"Prostaglandin F2 alpha"[tw] OR "F2 alpha, Prostaglandin"[tw] OR "9alpha, 
11beta-PGF2"[tw] OR "9alpha, 11beta PGF2"[tw] OR "PGF2 alpha"[tw] OR 
"alpha, PGF2"[tw] OR "Estrofan"[tw] OR "Enzaprost F"[tw] OR "PGF2alpha"[tw]) 
OR ("Oxytocics"[MeSH Terms] OR "Oxytocics"[tw] OR "Oxytocics"[All Fields]) 
OR ("Prostaglandins, Synthetic"[MeSH Terms] OR "Prostaglandins, 
Synthetic"[All Fields] OR "Prostaglandins, Synthetic"[tw] OR "Synthetic 
Prostaglandins"[tw] OR "PG Analogs"[tw] OR "Prostaglandin Analogues"[tw] OR 
"Prostaglandin Analogs"[tw]) OR ("misoprostol"[MeSH Terms] OR 
"misoprostol"[tw] OR "misoprostol"[All Fields] OR "SC-29333"[tw] OR "SC 
29333"[tw] OR "SC29333"[tw] OR "SC-30249"[tw] OR "SC 30249"[tw] OR 
"Cytotec"[tw]) OR ("Prostaglandins F, Synthetic"[MeSH Terms] OR 
"Prostaglandins F, Synthetic"[tw] OR "Prostaglandins F, Synthetic"[All Fields] OR 
"Synthetic Prostaglandins F"[tw] OR "Prostaglandin F Analogues"[tw] OR 
"Prostaglandin F Analogs"[tw]) OR ("Carboprost"[MeSH Terms] OR 
1688 
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"Carboprost"[tw] OR "Carboprost"[All Fields] OR "15-Methylprostaglandin 
F2alpha"[tw] OR "15 Methylprostaglandin F2alpha"[tw] OR "15(S)-15-Methyl 
PGF2alpha"[tw]) OR ("Abortifacient Agents, Nonsteroidal"[MeSH Terms] OR 
"Abortifacient Agents, Nonsteroidal"[tw] OR "Abortifacient Agents, 
Nonsteroidal"[All Fields]) OR ("fenprostalene"[Supplementary Concept] OR 
"fenprostalene"[All Fields] OR "fenprostalene"[tw]) OR 
("meteneprost"[Supplementary Concept] OR "meteneprost"[All Fields] OR 
"meteneprost"[tw] OR "9-methylene-PGE2"[tw] OR "9-methylene-16,16-dimethyl 
PGE2"[tw] OR "9-deoxo-16,16-dimethyl-9-methylene-PGE2"[tw]) OR 
("sulprostone"[Supplementary Concept] OR "sulprostone"[All Fields] OR 
"sulprostone"[tw] OR "sulproston"[tw] OR "methylsulfonylamide"[tw] OR "16-
phenoxy-omega-17,18,19,20-tetranor-PGE2 methylsulfonylamide"[tw] OR "ZK-
57671"[tw] OR "SHB 286"[tw] OR "CP-34089"[tw] OR "Nalador"[tw]) OR 
("Prostaglandins F"[MeSH Terms] OR "Prostaglandins F"[All Fields] OR 
"Prostaglandins F"[tw] OR "PGF"[tw]) OR ("Prostaglandins E, Synthetic"[MeSH 
Terms] OR "Prostaglandins E, Synthetic"[All Fields] OR "Prostaglandins E, 
Synthetic"[tw] OR "Synthetic Prostaglandins E"[tw] OR "PGE Synthetic"[tw] OR 
"Prostaglandin E Analogues"[tw] OR "Prostaglandin E Analogs"[tw]) OR 
("Prostaglandins E"[MeSH Terms] OR "Prostaglandins E"[All Fields] OR 
"Prostaglandins E"[tw] OR "PGE"[tw]) OR ("F2-Isoprostanes"[MeSH Terms] OR 
"F2-Isoprostanes"[All Fields] OR "F2-Isoprostanes"[tw] OR "F2 Isoprostanes"[tw] 
OR "F2-Isoprostane"[tw] OR "F2 Isoprostane"[tw]) OR ("prostaglandin E1 methyl 
ester"[Supplementary Concept] OR "prostaglandin E1 methyl ester"[All Fields] 
OR "prostaglandin E1 methyl ester"[tw] OR "PGE(1) methyl ester"[tw] OR "PGE1 
methyl ester"[tw] OR "Prostaglandin E(1) methyl ester"[tw]) OR ("prostaglandin 
E2 ethanolamide"[Supplementary Concept] OR "prostaglandin E2 
ethanolamide"[All Fields] OR "prostaglandin E2 ethanolamide"[tw] OR "PGE(2) 
ethanolamide"[tw] OR "Prostaglandin E(2) ethanolamide"[tw]) OR ("6-keto-
prostaglandin F2alpha"[Supplementary Concept] OR "6-keto-prostaglandin 
F2alpha"[All Fields] OR "6-keto-prostaglandin F2alpha"[tw] OR "6-keto-
prostaglandin F2 alpha"[tw] OR "6-keto-PGF2alpha"[tw]) OR 
("gemeprost"[Supplementary Concept] OR "gemeprost"[All Fields] OR 
"gemeprost"[tw] OR "Cervagem"[tw] OR "Cergem"[tw] OR "ONO 802"[tw] OR 
"ONO-802"[tw] OR "PG802"[tw]) OR ("Prostaglandin F2alpha 
ethanolamide"[Supplementary Concept] OR "Prostaglandin F2alpha 
ethanolamide"[All Fields] OR "Prostaglandin F2alpha ethanolamide"[tw] OR 
"PGF(2alpha) 1-ethanolamide"[tw] OR "Prostamide F(2alpha)"[tw]) OR ("2,3-
dinor-8-iso-prostaglandin-F(2alpha)"[Supplementary Concept] OR "2,3-dinor-8-
iso-prostaglandin-F(2alpha)"[All Fields] OR "2,3-dinor-8-iso-prostaglandin-
F(2alpha)"[tw]) OR ("2,3-dinor-5,6-dihydro-8-iso-prostaglandin 
F2(alpha)"[Supplementary Concept] OR "2,3-dinor-5,6-dihydro-8-iso-
prostaglandin F2(alpha)"[All Fields] OR "2,3-dinor-5,6-dihydro-8-iso-
prostaglandin F2(alpha)"[tw] OR "2,3-dinor-5,6-dihydro-8-iso-PGF2alpha"[tw]) 
OR ("17-phenyl-18,19,20-trinor-prostaglandin F2 alpha-1-isopropyl 
ester"[Supplementary Concept] OR "17-phenyl-18,19,20-trinor-prostaglandin F2 
alpha-1-isopropyl ester"[All Fields] OR "17-phenyl-18,19,20-trinor-prostaglandin 
F2 alpha-1-isopropyl ester"[tw] OR "PhDH100A"[tw] OR "17-phenyl-18,19,20-
trinor-PGF2alpha-1-isopropyl ester"[tw]) OR ("16-methyl prostaglandin 
E2"[Supplementary Concept] OR "16-methyl prostaglandin E2"[All Fields] OR 
"16-methyl prostaglandin E2"[tw] OR "16-methyl PGE2"[tw]) OR ("Dinoprost 
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tromethamine"[Supplementary Concept] OR "Dinoprost tromethamine"[All 
Fields] OR "Dinoprost tromethamine"[tw] OR "PGF2alpha tromethamine"[tw] OR 
"prostaglandin F2alpha tromethamine"[tw] OR "Lutalyse"[tw] OR "Minprostin F2 
Alpha"[tw] OR "Prostin F2"[tw] OR "Prostin F2 Alpha"[tw]) OR ("Carboprost 
tromethamine"[Supplementary Concept] OR "Carboprost tromethamine"[All 
Fields] OR "Carboprost tromethamine"[tw] OR "carboprost trometamol"[tw] OR 
"Hemabate"[tw])) AND ((("labor stage, third"[MeSH Terms] OR "labor stage, 
third"[tw] OR "labor stage, third"[All Fields] OR "Third Labor Stage"[tw] OR "Third 
Stage Labor"[tw]) OR ("uterine hemorrhage"[All Fields] OR "uterine 
hemorrhage"[MeSH Terms] OR "Uterine Hemorrhage"[All Fields] OR "Uterine 
Bleeding"[tw] OR "Uterine Bleedings"[tw] OR "Uterine Hemorrhages"[tw]) OR 
("puerperal disorders"[MeSH Terms] OR "Puerperal Disorders"[tw] OR 
"puerperal disorders"[All Fields] OR "Puerperal Disorder"[tw]) OR ("postpartum 
hemorrhage"[All Fields] OR "postpartum hemorrhage"[MeSH Terms] OR 
"Postpartum Hemorrhage"[tw] OR "Immediate Postpartum Hemorrhage"[tw] OR 
"Delayed Postpartum Hemorrhage"[tw]) OR ("Obstetric Labor 
Complications"[MeSH Terms] OR "Obstetric Labor Complications"[All Fields] OR 
"Obstetric Labor Complications"[tw] OR "Labor Complications"[tw] OR "Labor 
Complication"[tw]) OR ((("Placenta"[MeSH Terms] OR "Placenta"[tw]) AND 
"retained"[All Fields]) OR "Placenta, retained"[MeSH Terms] OR "retained 
placenta"[tw] OR "Retained Placentas"[tw] OR "Retained Placenta"[tw]) OR 
("Placenta Diseases"[MeSH Terms] OR "Placenta Diseases"[All Fields] OR 
"Placenta Diseases"[tw] OR "Placental Diseases"[tw] OR "Disease, 
Placental"[tw] OR "Placental Disease"[tw] OR "Placenta Disorders"[tw])) AND 
(randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized 
controlled trials[mh] OR random allocation[mh] OR double-blind method[mh] OR 
single-blind method[mh] OR clinical trial[pt] OR clinical trials[mh] OR ((clinical 
trial[tw]) OR ((singl*[tw] OR doubl*[tw] OR trebl*[tw] OR tripl*[tw]) AND 
(mask*[tw] OR blind[tw])) OR (latin square[tw]) OR placebos[mh] OR 
placebo*[tw] OR random*[tw] OR research design[mh:noexp] OR comparative 
study[pt] OR evaluation studies[pt] OR follow-up studies[mh] OR prospective 
studies[mh] OR cross-over studies[mh] OR control*[tw] OR prospectiv*[tw] OR 
volunteer*[tw]) NOT (animal[mh] NOT human[mh]))) 
#41 Search #40 AND #10 1688 
#40 Search #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 
OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR 
#29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 
OR #39 
15542
6 
#39 Search "Carboprost tromethamine"[Supplementary Concept] OR "Carboprost 
tromethamine"[All Fields] OR "Carboprost tromethamine"[tw] OR "carboprost 
trometamol"[tw] OR "Hemabate"[tw] 
23 
#38 Search "Dinoprost tromethamine"[Supplementary Concept] OR "Dinoprost 
tromethamine"[All Fields] OR "Dinoprost tromethamine"[tw] OR "PGF2alpha 
tromethamine"[tw] OR "prostaglandin F2alpha tromethamine"[tw] OR 
"Lutalyse"[tw] OR "Minprostin F2 Alpha"[tw] OR "Prostin F2"[tw] OR "Prostin F2 
Alpha"[tw] 
151 
#37 Search “16-methyl prostaglandin E2” [Supplementary Concept] OR “16-methyl 
prostaglandin E2” [All Fields] OR “16-methyl prostaglandin E2” [tw] OR “16-
methyl PGE2” [tw] 
2 
#36 Search “17-phenyl-18,19,20-trinor-prostaglandin F2 alpha-1-isopropyl ester” 4 
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[Supplementary Concept] OR “17-phenyl-18,19,20-trinor-prostaglandin F2 alpha-
1-isopropyl ester” [All Fields] OR “17-phenyl-18,19,20-trinor-prostaglandin F2 
alpha-1-isopropyl ester” [tw] OR “PhDH100A” [tw] OR “17-phenyl-18,19,20-
trinor-PGF2alpha-1-isopropyl ester” [tw] 
#35 Search "2,3-dinor-5,6-dihydro-8-iso-prostaglandin F2(alpha)"[Supplementary 
Concept] OR "2,3-dinor-5,6-dihydro-8-iso-prostaglandin F2(alpha)"[All Fields] 
OR "2,3-dinor-5,6-dihydro-8-iso-prostaglandin F2(alpha)"[tw] OR "2,3-dinor-5,6-
dihydro-8-iso-PGF2alpha"[tw] 
8 
#34 Search "2,3-dinor-8-iso-prostaglandin-F(2alpha)"[Supplementary Concept] OR 
"2,3-dinor-8-iso-prostaglandin-F(2alpha)"[All Fields] OR "2,3-dinor-8-iso-
prostaglandin-F(2alpha)"[tw] 
4 
#33 Search “Prostaglandin F2alpha ethanolamide” [Supplementary Concept] OR 
“Prostaglandin F2alpha ethanolamide” [All Fields] OR “Prostaglandin F2alpha 
ethanolamide” [tw] OR “PGF(2alpha) 1-ethanolamide” [tw] OR “Prostamide 
F(2alpha)” [tw] 
7 
#32 Search "gemeprost"[Supplementary Concept] OR "gemeprost"[All Fields] OR 
"gemeprost"[tw] OR "Cervagem"[tw] OR "Cergem"[tw] OR "ONO 802"[tw] OR 
"ONO-802"[tw] OR "PG802"[tw] 
355 
#31 Search “6-keto-prostaglandin F2alpha” [Supplementary Concept] OR “6-keto-
prostaglandin F2alpha” [All Fields] OR “6-keto-prostaglandin F2alpha” [tw] OR 
“6-keto-prostaglandin F2 alpha” [tw] OR “6-keto-PGF2alpha” [tw] 
29 
#30 Search "prostaglandin E2 ethanolamide"[Supplementary Concept] OR 
"prostaglandin E2 ethanolamide"[All Fields] OR "prostaglandin E2 
ethanolamide"[tw] OR "PGE(2) ethanolamide"[tw] OR "Prostaglandin E(2) 
ethanolamide"[tw] 
9 
#29 Search “prostaglandin E1 methyl ester” [Supplementary Concept] OR 
“prostaglandin E1 methyl ester” [All Fields] OR “prostaglandin E1 methyl ester” 
[tw] OR “PGE(1) methyl ester” [tw] OR “PGE1 methyl ester” [tw] OR 
“Prostaglandin E(1) methyl ester” [tw] 
96 
#28 Search “F2-Isoprostanes” [MeSH Terms] OR “F2-Isoprostanes” [All Fields] OR 
“F2-Isoprostanes” [tw] OR “F2 Isoprostanes” [tw] OR “F2-Isoprostane” [tw] OR 
“F2 Isoprostane” [tw] 
1065 
#27 Search "Prostaglandins E"[MeSH Terms] OR "Prostaglandins E"[All Fields] OR 
"Prostaglandins E"[tw] OR "PGE"[tw] 
40582 
#26 Search "Prostaglandins E, Synthetic"[MeSH Terms] OR "Prostaglandins E, 
Synthetic"[All Fields] OR "Prostaglandins E, Synthetic"[tw] OR "Synthetic 
Prostaglandins E"[tw] OR "PGE Synthetic"[tw] OR "Prostaglandin E 
Analogues"[tw] OR "Prostaglandin E Analogs"[tw] 
4728 
#25 Search "Prostaglandins F"[MeSH Terms] OR "Prostaglandins F"[All Fields] OR 
"Prostaglandins F"[tw] OR "PGF"[tw] 
21658 
#24 Search "sulprostone"[Supplementary Concept] OR "sulprostone"[All Fields] OR 
"sulprostone"[tw] OR "sulproston"[tw] OR "methylsulfonylamide"[tw] OR "16-
phenoxy-omega-17,18,19,20-tetranor-PGE2 methylsulfonylamide"[tw] OR "ZK-
57671"[tw] OR "SHB 286"[tw] OR "CP-34089"[tw] OR "Nalador"[tw] 
688 
#23 Search "meteneprost"[Supplementary Concept] OR "meteneprost"[All Fields] OR 
"meteneprost"[tw] OR "9-methylene-PGE2"[tw] OR "9-methylene-16,16-dimethyl 
PGE2"[tw] OR "9-deoxo-16,16-dimethyl-9-methylene-PGE2"[tw] 
56 
#22 Search "fenprostalene"[Supplementary Concept] OR "fenprostalene"[All Fields] 
OR "fenprostalene"[tw] 
53 
#21 Search “Abortifacient Agents, Nonsteroidal”[MeSH Terms] OR “Abortifacient 42280 
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Agents, Nonsteroidal” [tw] OR “Abortifacient Agents, Nonsteroidal” [All Fields] 
#20 Search “Carboprost”[MeSH Terms] OR “Carboprost” [tw] OR “Carboprost” [All 
Fields] OR “15-Methylprostaglandin F2alpha” [tw] OR “15 Methylprostaglandin 
F2alpha” [tw] OR “15(S)-15-Methyl PGF2alpha” [tw] 
241 
#19 Search "Prostaglandins F, Synthetic"[MeSH Terms] OR "Prostaglandins F, 
Synthetic"[tw] OR "Prostaglandins F, Synthetic"[All Fields] OR "Synthetic 
Prostaglandins F"[tw] OR "Prostaglandin F Analogues"[tw] OR "Prostaglandin F 
Analogs"[tw] 
2712 
#18 Search "misoprostol"[MeSH Terms] OR "misoprostol"[tw] OR "misoprostol"[All 
Fields] OR "SC-29333"[tw] OR "SC 29333"[tw] OR "SC29333"[tw] OR "SC-
30249"[tw] OR "SC 30249"[tw] OR "Cytotec"[tw] 
3633 
#17 Search "Prostaglandins, Synthetic"[MeSH Terms] OR "Prostaglandins, 
Synthetic"[All Fields] OR "Prostaglandins, Synthetic"[tw] OR "Synthetic 
Prostaglandins"[tw] OR "PG Analogs"[tw] OR "Prostaglandin Analogues"[tw] OR 
"Prostaglandin Analogs"[tw] 
12771 
#16 Search “Oxytocics” [MeSH Terms] OR “Oxytocics” [tw] OR “Oxytocics” [All 
Fields] 
53082 
#15 Search “dinoprost”[MeSH Terms] OR “dinoprost”[All Fields] OR “dinoprost” [tw] 
OR “PGF2” [tw] OR “Prostaglandin F2alpha” [tw] OR “F2alpha, 
Prostaglandin”[tw] OR “PGF2alpha”[tw] OR “Prostaglandin F2”[tw] OR 
“Prostaglandin F2 alpha”[tw] OR “F2 alpha, Prostaglandin”[tw] OR 
“9alpha,11beta-PGF2”[tw] OR “9alpha,11beta PGF2”[tw] OR “PGF2 alpha”[tw] 
OR “alpha, PGF2”[tw] OR “Estrofan”[tw] OR “Enzaprost F”[tw] OR “PGF2α”[tw] 
16732 
#14 Search "prostaglandin E2 methyl ester"[Supplementary Concept] OR 
"prostaglandin E2 methyl ester"[All Fields] OR "prostaglandin E2 methyl 
ester"[tw] OR "PGE2 methyl ester"[tw] 
80 
#13 Search "prostaglandin F1"[Supplementary Concept] OR "prostaglandin F1"[All 
Fields] OR "prostaglandin F1"[tw] OR "PGF1"[tw] OR "prostaglandin 
F1alpha"[tw] OR "PGF1alpha"[tw] OR "PGF1 alpha"[tw] 
5794 
#12 Search "dinoprostone"[MeSH Terms] OR "dinoprostone"[All Fields] OR 
"dinoprostone"[tw] OR "PGE2 alpha"[tw] OR "alpha, PGE2"[tw] OR 
"PGE2alpha"[tw] OR "Prostaglandin E2 alpha"[tw] OR "alpha, Prostaglandin 
E2"[tw] OR "Prostaglandin E2alpha"[tw] OR "PGE2"[tw] OR "Prostaglandin 
E2"[tw] OR "E2, Prostaglandin"[tw] OR "Prepidil Gel"[tw] OR "Prostenon"[tw] 
33917 
#11 Search “prostaglandins”[MeSH Terms] OR “prostaglandins” [tw] OR 
“prostanoids” [tw] OR “prostaglandins”[All Fields] 
96861 
#10 Search #9 AND #1 26187 
#9 Search #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 80238 
#8 Search "Placenta Diseases"[MeSH Terms] OR "Placenta Diseases"[All Fields] 
OR "Placenta Diseases"[tw] OR "Placental Diseases"[tw] OR "Disease, 
Placental"[tw] OR "Placental Disease"[tw] OR "Placenta Disorders"[tw] 
11061 
#7 Search (("Placenta"[MeSH Terms] OR "Placenta"[tw]) AND "retained"[All Fields]) 
OR "Placenta, retained"[MeSH Terms] OR "retained placenta"[tw] OR "Retained 
Placentas"[tw] OR "Retained Placenta"[tw] 
1429 
#6 Search "Obstetric Labor Complications"[MeSH Terms] OR "Obstetric Labor 
Complications"[All Fields] OR "Obstetric Labor Complications"[tw] OR "Labor 
Complications"[tw] OR "Labor Complication"[tw] 
44655 
#5 Search "postpartum hemorrhage"[All Fields] OR "postpartum 
hemorrhage"[MeSH Terms] OR "Postpartum Hemorrhage"[tw] OR "Immediate 
4621 
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Postpartum Hemorrhage"[tw] OR "Delayed Postpartum Hemorrhage"[tw] 
#4 Search "puerperal disorders"[MeSH Terms] OR "Puerperal Disorders"[tw] OR 
"puerperal disorders"[All Fields] OR "Puerperal Disorder"[tw] 
23730 
#3 Search "uterine hemorrhage"[All Fields] OR "uterine hemorrhage"[MeSH Terms] 
OR "Uterine Hemorrhage"[All Fields] OR "Uterine Bleeding"[tw] OR "Uterine 
Bleedings"[tw] OR "Uterine Hemorrhages"[tw] 
16348 
#2 Search "labor stage, third"[MeSH Terms] OR "labor stage, third"[tw] OR "labor 
stage, third"[All Fields] OR "Third Labor Stage"[tw] OR "Third Stage Labor"[tw] 
574 
#1 Search (randomized controlled trial [pt] OR controlled clinical trial [pt] OR 
randomized controlled trials [mh] OR random allocation [mh] OR double-blind 
method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials 
[mh] OR ((clinical trial [tw]) OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* 
[tw]) AND (mask* [tw] OR blind [tw])) OR (latin square [tw]) OR placebos [mh] 
OR placebo* [tw] OR random* [tw] OR research design [mh:noexp] OR 
comparative study [pt] OR evaluation studies [pt] OR follow-up studies [mh] OR 
prospective studies [mh] OR cross-over studies [mh] OR control* [tw] OR 
prospectiv* [tw] OR volunteer* [tw]) NOT (animal [mh] NOT human [mh]) 
40851
09 
 
 
Embase database 
Search Date: 27/05/2011 
 
#47 
#1 AND #10 AND #46 
5,134 
#46 
#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR 
#21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR 
#31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR 
#41 OR #42 OR #43 OR #44 OR #45 
533,166 
#45 
oxytocic AND agent OR 'oxytocic agent'/exp/mj OR 'oxytocic agent'/syn OR 'oxytocic 
agent'/exp OR 'oxytocic agent' OR 'labor inducing drug'/exp OR 'labor inducing drug' 
OR 'ocytocic agent'/exp OR 'ocytocic agent' OR 'oxytocic activity'/exp OR 'oxytocic 
activity' OR 'oxytocic substance'/exp OR 'oxytocic substance' OR 'oxytocics'/exp OR 
'oxytocics' 
2,168 
#44 
'sulprostone'/exp/mj OR 'sulprostone'/syn OR 'sulprostone'/exp OR 'sulprostone' OR '16 
phenoxy 17, 18, 19, 20 tetranorprostaglandin e2 methylsulfonamide'/exp OR '16 
phenoxy 17, 18, 19, 20 tetranorprostaglandin e2 methylsulfonamide' OR '16 phenoxy 
17, 18, 19, 20 tetranorprostaglandin e2 methylsulfonylamide'/exp OR '16 phenoxy 17, 
18, 19, 20 tetranorprostaglandin e2 methylsulfonylamide' OR '16 phenoxy omega 
tetranordinoprostone methylsulfonamide'/exp OR '16 phenoxy omega 
tetranordinoprostone methylsulfonamide' OR '16 phenoxy omega tetranorprostaglandin 
e2 methanesulfonamide'/exp OR '16 phenoxy omega tetranorprostaglandin e2 
methanesulfonamide' OR '16 phenoxy omega tetranorprostaglandin e2 methyl 
sulfonamide'/exp OR '16 phenoxy omega tetranorprostaglandin e2 methyl sulfonamide' 
OR '16 phenoxy omega tetranorprostaglandin e2 methylsulfonylamide'/exp OR '16 
phenoxy omega tetranorprostaglandin e2 methylsulfonylamide' OR '17, 18, 19, 20 
tetranor 16 phenoxyprostaglandin e2 methyl sulfonamide'/exp OR '17, 18, 19, 20 
tetranor 16 phenoxyprostaglandin e2 methyl sulfonamide' OR '7 [3 hydroxy 2 (3 
1,216 
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hydroxy 4 phenoxy 1 butenyl) 5 oxocyclopentyl] n (methylsulfonyl) 5 heptenamide'/exp 
OR '7 [3 hydroxy 2 (3 hydroxy 4 phenoxy 1 butenyl) 5 oxocyclopentyl] n 
(methylsulfonyl) 5 heptenamide' OR 'cp 34, 089'/exp OR 'cp 34, 089' OR 'cp 34089'/exp 
OR 'cp 34089' OR 'cp34, 089'/exp OR 'cp34, 089' OR 'cp34089'/exp OR 'cp34089' OR 
'nalador'/exp OR 'nalador' OR 'nalador 500'/exp OR 'nalador 500' OR 'prostaglandin e2 
methylsulfonamide, 16 phenoxy 17, 18, 19, 20 tetranor'/exp OR 'prostaglandin e2 
methylsulfonamide, 16 phenoxy 17, 18, 19, 20 tetranor' OR 'prostaglandin e2 
methylsulfonylamide, 16 phenoxy omega tetranor'/exp OR 'prostaglandin e2 
methylsulfonylamide, 16 phenoxy omega tetranor' OR 'prostaglandin e2, 17, 18, 19, 20 
tetranor 16 phenoxy methylsulfonamide'/exp OR 'prostaglandin e2, 17, 18, 19, 20 
tetranor 16 phenoxy methylsulfonamide' OR 'shb 286'/exp OR 'shb 286' OR 
'shb286'/exp OR 'shb286' OR 'zk 57671'/exp OR 'zk 57671' OR 'zk57671'/exp OR 
'zk57671' 
#43 
'prostalene'/exp/mj OR 'prostalene'/syn OR 'prostalene'/exp OR 'prostalene' OR '7 [3, 5 
dihydroxy 2 (3 hydroxy 3 methyl 1 octenyl) cyclopentyl] 4, 5 heptadienoic acid methyl 
ester'/exp OR '7 [3, 5 dihydroxy 2 (3 hydroxy 3 methyl 1 octenyl) cyclopentyl] 4, 5 
heptadienoic acid methyl ester' OR 'rs 9390'/exp OR 'rs 9390' OR 'rs9390'/exp OR 
'rs9390' 
23 
#42 
'prostaglandin' OR 'prostaglandin'/exp OR prostaglandin AND f2 AND alpha AND 
isopropyl AND ('ester' OR 'ester'/exp OR ester) OR ('prostaglandin'/exp/mj OR 
'prostaglandin' OR 'prostaglandin'/exp OR prostaglandin AND f2 AND alpha AND 
isopropyl AND ('ester'/exp/mj OR 'ester' OR 'ester'/exp OR ester)) OR 
('prostaglandin'/syn OR 'prostaglandin' AND f2 AND alpha AND isopropyl AND 
('ester'/syn OR 'ester')) 
190 
#41 
8 AND isoprostaglandin AND f2 AND alpha OR '8 epiprostaglandin f2 alpha; 8 
isoprostaglandin f2alpha' OR 'prostaglandin f2 alpha, 8 iso'/exp OR 'prostaglandin f2 
alpha, 8 iso' 
830 
#40 
'prostaglandin' OR 'prostaglandin'/exp OR prostaglandin AND f2 AND alpha AND 
('trometamol' OR 'trometamol'/exp OR trometamol) OR ('prostaglandin'/exp/mj OR 
'prostaglandin' OR 'prostaglandin'/exp OR prostaglandin AND f2 AND alpha AND 
('trometamol'/exp/mj OR 'trometamol' OR 'trometamol'/exp OR trometamol)) OR 
('prostaglandin'/syn OR 'prostaglandin' AND f2 AND alpha AND ('trometamol'/syn OR 
'trometamol')) OR 'amoglandin'/exp OR 'amoglandin' OR 'dinoprost trometamol'/exp OR 
'dinoprost trometamol' OR 'dinoprost tromethamine'/exp OR 'dinoprost tromethamine' 
OR 'lutalyse'/exp OR 'lutalyse' OR 'minprostin f2 alpha'/exp OR 'minprostin f2 alpha' OR 
'minprostin f2alpha'/exp OR 'minprostin f2alpha' OR 'pgf2alpha tham'/exp OR 
'pgf2alpha tham' OR 'prostaglandin f2 alpha tromethamine'/exp OR 'prostaglandin f2 
alpha tromethamine' OR 'u 14583e'/exp OR 'u 14583e' OR 'u14583e'/exp OR 'u14583e' 
660 
#39 
13, AND 14 AND dihydro AND 15 AND oxoprostaglandin AND f2 AND alpha OR '13, 
14 dihydro 15 ketoprostaglandin f2 alpha'/exp OR '13, 14 dihydro 15 ketoprostaglandin 
f2 alpha' OR '13, 14 dihydro 15 oxodinoprost'/exp OR '13, 14 dihydro 15 oxodinoprost' 
OR '15 keto 13, 14 dihydroprostaglandin f2 alpha'/exp OR '15 keto 13, 14 
dihydroprostaglandin f2 alpha' OR '15 oxo 13, 14 dihydrodinoprost'/exp OR '15 oxo 13, 
14 dihydrodinoprost' OR '15 oxo 13, 14 dihydroprostaglandin f2 alpha'/exp OR '15 oxo 
13, 14 dihydroprostaglandin f2 alpha' OR 'dinoprost, 13, 14 dihydro 15 oxo'/exp OR 
380 
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'dinoprost, 13, 14 dihydro 15 oxo' OR 'prostaglandin f2 alpha, 13, 14 dihydro 15 
oxo'/exp OR 'prostaglandin f2 alpha, 13, 14 dihydro 15 oxo' 
#38 
'prostaglandin' OR 'prostaglandin'/exp OR prostaglandin AND f2 AND alpha AND 
derivative OR ('prostaglandin'/exp/mj OR 'prostaglandin' OR 'prostaglandin'/exp OR 
prostaglandin AND f2 AND alpha AND derivative) OR ('prostaglandin'/syn OR 
'prostaglandin' AND f2 AND alpha AND derivative) OR 'dinoprost derivative'/exp OR 
'dinoprost derivative' 
13,239 
#37 
'prostaglandin' OR 'prostaglandin'/exp OR prostaglandin AND f2 AND alpha OR 
('prostaglandin'/exp/mj OR 'prostaglandin' OR 'prostaglandin'/exp OR prostaglandin 
AND f2 AND alpha) OR ('prostaglandin'/syn OR 'prostaglandin' AND f2 AND alpha) OR 
'dinolytic; dinoprost' OR 'dinoprost sodium; ensaprost f' OR 'enzaprost; enzaprost f' OR 
'pg f2 alpha; pgf 2 alpha' OR 'pgf 2a; pgf2 alpha' OR 'pgf2a; pgf2alpha' OR 
'prostaglandin f 2 a; prostaglandin f 2 alpha' OR 'prostaglandin f 2a; prostaglandin f 
2alpha' OR 'prostaglandin f2 a; prostaglandin f2a' OR 'prostaglandin f2alpha; 
prostalmon f' OR 'prostarmon f; prostin f 2 alpha' OR 'prostin f2 alpha; u 14583' OR 
'u14583'/exp OR 'u14583' 
21,731 
#36 
'isoprostane' OR 'isoprostane'/exp OR isoprostane AND derivative OR 
('isoprostane'/exp/mj OR 'isoprostane' OR 'isoprostane'/exp OR isoprostane AND 
derivative) OR ('isoprostane'/syn OR 'isoprostane' AND derivative) OR 'f2-
isoprostanes'/exp OR 'f2-isoprostanes' OR 'f2 isoprostanes'/exp OR 'f2 isoprostanes' 
OR 'isoprostanes'/exp OR 'isoprostanes' 
3,206 
#35 
'prostaglandin' OR 'prostaglandin'/exp OR prostaglandin AND f1 AND alpha OR 
('prostaglandin'/exp/mj OR 'prostaglandin' OR 'prostaglandin'/exp OR prostaglandin 
AND f1 AND alpha) OR ('prostaglandin'/syn OR 'prostaglandin' AND f1 AND alpha) OR 
'pgf 1 alpha'/exp OR 'pgf 1 alpha' OR 'pgf1 alpha'/exp OR 'pgf1 alpha' OR 'pgf1a'/exp 
OR 'pgf1a' OR 'prostaglandin f 1 alpha'/exp OR 'prostaglandin f 1 alpha' OR 
'prostaglandin f 1a'/exp OR 'prostaglandin f 1a' OR 'prostaglandin f1 a'/exp OR 
'prostaglandin f1 a' OR 'prostaglandin f1a'/exp OR 'prostaglandin f1a' OR 'prostaglandin 
f1alpha'/exp OR 'prostaglandin f1alpha' 
6,630 
#34 
'prostaglandin' OR 'prostaglandin'/exp OR prostaglandin AND f OR 'prostaglandin 
f'/exp/mj OR 'prostaglandin f'/syn OR 'prostaglandin f'/exp OR 'prostaglandin f' OR 'pgf; 
prostaglandins f' OR 'prostaglandins f, synthetic'/exp OR 'prostaglandins f, synthetic' 
94,258 
#33 
'prostaglandin' OR 'prostaglandin'/exp OR prostaglandin AND f2 OR 'prostaglandin 
f2'/exp/mj OR 'prostaglandin f2'/syn OR 'prostaglandin f2'/exp OR 'prostaglandin f2' OR 
'pgf2'/exp OR 'pgf2' OR 'prostaglandin f 2'/exp OR 'prostaglandin f 2' OR 'prostglandin 
f2'/exp OR 'prostglandin f2' 
24,655 
#32 
'prostaglandin' OR 'prostaglandin'/exp OR prostaglandin AND e2 AND derivative OR 
'prostaglandin e2 derivative'/exp/mj OR 'prostaglandin e2 derivative'/syn OR 
'prostaglandin e2 derivative'/exp OR 'prostaglandin e2 derivative' OR 'dinoprostone 
derivative'/exp OR 'dinoprostone derivative' 
28,417 
#31 
'prostaglandin' OR 'prostaglandin'/exp OR prostaglandin AND e2 AND ('trometamol' OR 
'trometamol'/exp OR trometamol) OR 'prostaglandin e2 trometamol'/exp/mj OR 
178 
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'prostaglandin e2 trometamol'/syn OR 'prostaglandin e2 trometamol'/exp OR 
'prostaglandin e2 trometamol' OR 'dinoprostone trometamol'/exp OR 'dinoprostone 
trometamol' OR 'dinoprostone tromethamine'/exp OR 'dinoprostone tromethamine' OR 
'minprostin e 2'/exp OR 'minprostin e 2' OR 'minprostin e2'/exp OR 'minprostin e2' OR 
'prostaglandin e2 tromethamine'/exp OR 'prostaglandin e2 tromethamine' 
#30 
'prostaglandin' OR 'prostaglandin'/exp OR prostaglandin AND e2 AND methyl AND 
('ester' OR 'ester'/exp OR ester) OR 'prostaglandin e2 methyl ester'/exp/mj OR 
'prostaglandin e2 methyl ester'/syn OR 'prostaglandin e2 methyl ester'/exp OR 
'prostaglandin e2 methyl ester' OR 'dl prostaglandin e237 methyl ester'/exp OR 'dl 
prostaglandin e237 methyl ester' OR 'methyl dl 15 hydroxy 9 oxoprost 8 (12) 
enoate'/exp OR 'methyl dl 15 hydroxy 9 oxoprost 8 (12) enoate' OR 'prostaglandin e 
237 methyl ester'/exp OR 'prostaglandin e 237 methyl ester' 
897 
#29 
'prostaglandin' OR 'prostaglandin'/exp OR prostaglandin AND e2 OR 'prostaglandin 
e2'/exp/mj OR 'prostaglandin e2'/syn OR 'prostaglandin e2'/exp OR 'prostaglandin e2' 
OR '11, 15 dihydroxy 9 oxoprosta 5, 13 dien 1 oic acid'/exp OR '11, 15 dihydroxy 9 
oxoprosta 5, 13 dien 1 oic acid' OR 'cervidil'/exp OR 'cervidil' OR 'cerviprimet' OR 
'cerviprime'/exp OR 'cerviprime' OR 'cerviprost'/exp OR 'cerviprost' OR 'dinoprostin'/exp 
OR 'dinoprostin' OR 'dinoprostone'/exp OR 'dinoprostone' OR 'dinoprostone 
sodium'/exp OR 'dinoprostone sodium' OR 'org 2634'/exp OR 'org 2634' OR 
'org2634'/exp OR 'org2634' OR 'pg e2'/exp OR 'pg e2' OR 'pge 2'/exp OR 'pge 2' OR 
'pge2'/exp OR 'pge2' OR 'pge'/exp OR 'pge' OR 'postaglandin e 2'/exp OR 
'postaglandin e 2' OR 'prepidil'/exp OR 'prepidil' OR 'prepidil gel'/exp OR 'prepidil gel' 
OR 'propess'/exp OR 'propess' OR 'prostaglandin e 2'/exp OR 'prostaglandin e 2' OR 
'prostaglandin e ii'/exp OR 'prostaglandin e ii' OR 'prostaglandin e2 release'/exp OR 
'prostaglandin e2 release' OR 'prostaglandine e2'/exp OR 'prostaglandine e2' OR 
'prostarmon e'/exp OR 'prostarmon e' OR 'prostenon'/exp OR 'prostenon' OR 
'prostin'/exp OR 'prostin' OR 'prostin e2'/exp OR 'prostin e2' OR 'prostin r'/exp OR 
'prostin r' OR 'u 12062'/exp OR 'u 12062' OR 'u12062'/exp OR 'u12062' 
62,917 
#28 
'prostaglandin' OR 'prostaglandin'/exp OR prostaglandin AND derivative OR 
('prostaglandin'/exp/mj OR 'prostaglandin' OR 'prostaglandin'/exp OR prostaglandin 
AND derivative) OR ('prostaglandin'/exp/mj OR 'prostaglandin'/syn OR 'prostaglandin' 
AND derivative) OR '16, 16 dimethylprostaglandin'/exp OR '16, 16 
dimethylprostaglandin' OR '8 methylprostaglandin derivative'/exp OR '8 
methylprostaglandin derivative' OR 'methylprostaglandin'/exp OR 'methylprostaglandin' 
OR 'prostaglandin 1'/exp OR 'prostaglandin 1' OR 'prostaglandin analog'/exp OR 
'prostaglandin analog' OR 'prostaglandins, synthetic'/exp OR 'prostaglandins, synthetic' 
429,204 
#27 
17, AND 20 AND dimethyl AND 7 AND thiaprostaglandin AND e1 AND methyl AND 
('ester' OR 'ester'/exp OR ester) OR '17, 20 dimethyl 7 thiaprostaglandin e1 methyl 
ester'/exp/mj OR '17, 20 dimethyl 7 thiaprostaglandin e1 methyl ester'/syn OR '17, 20 
dimethyl 7 thiaprostaglandin e1 methyl ester'/exp OR '17, 20 dimethyl 7 
thiaprostaglandin e1 methyl ester' OR '11, 15 dihydroxy 17, 20 dimethyl 9 oxo 7 
thiaprost 13 en 1 oic acid methyl ester'/exp OR '11, 15 dihydroxy 17, 20 dimethyl 9 oxo 
7 thiaprost 13 en 1 oic acid methyl ester' OR 'prostaglandin e1 methyl ester, 7 thia 17, 
20 dimethyl'/exp OR 'prostaglandin e1 methyl ester, 7 thia 17, 20 dimethyl' OR 'tei 
6122'/exp OR 'tei 6122' OR 'tei6122'/exp OR 'tei6122' OR 'tfc 612'/exp OR 'tfc 612' OR 
'tfc612'/exp OR 'tfc612' 
21 
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#26 
'prostaglandin' OR 'prostaglandin'/exp OR prostaglandin AND e OR 'prostaglandin 
e'/exp/mj OR 'prostaglandin e'/syn OR 'prostaglandin e'/exp OR 'prostaglandin e' OR 
'pge'/exp OR 'pge' OR 'prostaglandins e'/exp OR 'prostaglandins e' OR 'prostaglandins 
e, synthetic'/exp OR 'prostaglandins e, synthetic' 
149,126 
#25 
'misoprostol'/exp/mj OR 'misoprostol'/syn OR 'misoprostol'/exp OR 'misoprostol' OR '1, 
16 dihydroxy 16 methyl 9 oxo 13 prostenoic acid methyl ester' OR '11, 16 dihydroxy 16 
methyl 9 oxoprost 13 enoic acid methyl ester'/exp OR '11, 16 dihydroxy 16 methyl 9 
oxoprost 13 enoic acid methyl ester' OR '15 deoxy 16 hydroxy 16 methylprostaglandin 
e1 methyl ester'/exp OR '15 deoxy 16 hydroxy 16 methylprostaglandin e1 methyl ester' 
OR '3 hydroxy 2 (4 hydroxy 4 methyl 1 octenyl) 5 oxocyclopentaneheptanoic acid 
methyl ester'/exp OR '3 hydroxy 2 (4 hydroxy 4 methyl 1 octenyl) 5 
oxocyclopentaneheptanoic acid methyl ester' OR 'cytotec'/exp OR 'cytotec' OR 
'gymiso'/exp OR 'gymiso' OR 'misopress'/exp OR 'misopress' OR 'misoprostil'/exp OR 
'misoprostil' OR 'prostaglandin e1 methylester, 15 deoxy 16 hydroxy 16 methyl'/exp OR 
'prostaglandin e1 methylester, 15 deoxy 16 hydroxy 16 methyl' OR 'sc 29333'/exp OR 
'sc 29333' OR 'sc 30249'/exp OR 'sc 30249' OR 'sc29333'/exp OR 'sc29333' OR 
'sc30249'/exp OR 'sc30249' OR 'xp 16j'/exp OR 'xp 16j' OR 'xp16j'/exp OR 'xp16j' 
7,986 
#24 
'meteneprost'/exp/mj OR 'meteneprost'/syn OR 'meteneprost'/exp OR 'meteneprost' OR 
'7 [3 hydroxy 2 (3 hydroxy 4, 4 dimethyl 1 octenyl) 5 methylenecyclopentyl] 5 heptenoic 
acid'/exp OR '7 [3 hydroxy 2 (3 hydroxy 4, 4 dimethyl 1 octenyl) 5 
methylenecyclopentyl] 5 heptenoic acid' OR '9 deoxo 16, 16 dimethyl 9 
methylenedinoprostone'/exp OR '9 deoxo 16, 16 dimethyl 9 methylenedinoprostone' 
OR '9 deoxo 16, 16 dimethyl 9 methyleneprostaglandin e2'/exp OR '9 deoxo 16, 16 
dimethyl 9 methyleneprostaglandin e2' OR '9 deoxy 16, 16 dimethyl 9 
methyleneprostaglandin e2'/exp OR '9 deoxy 16, 16 dimethyl 9 methyleneprostaglandin 
e2' OR 'u 46785'/exp OR 'u 46785' OR 'u 46785 b'/exp OR 'u 46785 b' OR 'u 
46785b'/exp OR 'u 46785b' OR 'u46785'/exp OR 'u46785' OR 'u46785b'/exp OR 
'u46785b' 
94 
#23 
'gemeprost'/exp/mj OR 'gemeprost'/syn OR 'gemeprost'/exp OR 'gemeprost' OR '11, 15 
dihydroxy 16, 16 dimethyl 9 oxoprosta 2, 13 dienoic acid methyl ester'/exp OR '11, 15 
dihydroxy 16, 16 dimethyl 9 oxoprosta 2, 13 dienoic acid methyl ester' OR '16, 16 
dimethyl delta2 prostaglandin e1 methyl ester'/exp OR '16, 16 dimethyl delta2 
prostaglandin e1 methyl ester' OR '7 [3 hydroxy 3 (hydroxy 4, 4 dimethyl 1 octenyl) 5 
oxocyclopentyl] 2 heptenoic acid methyl ester'/exp OR '7 [3 hydroxy 3 (hydroxy 4, 4 
dimethyl 1 octenyl) 5 oxocyclopentyl] 2 heptenoic acid methyl ester' OR 'cergem'/exp 
OR 'cergem' OR 'cervagem'/exp OR 'cervagem' OR 'ono 802'/exp OR 'ono 802' OR 
'ono802'/exp OR 'ono802' OR 'prosta 2, 5 diene 11, 15 diol 9 on 1 oic acid methyl ester, 
16, 16 dimethyl'/exp OR 'prosta 2, 5 diene 11, 15 diol 9 on 1 oic acid methyl ester, 16, 
16 dimethyl' OR 'sc 37681'/exp OR 'sc 37681' OR 'sc37681'/exp OR 'sc37681' 
653 
#22 
'fluprostenol'/exp/mj OR 'fluprostenol'/syn OR 'fluprostenol'/exp OR 'fluprostenol' OR '16 
(3 trifluoromethylphenoxy) 17, 18, 19, 20 tetranordinoprost'/exp OR '16 (3 
trifluoromethylphenoxy) 17, 18, 19, 20 tetranordinoprost' OR '16 (3 
trifluoromethylphenoxy) 17, 18, 19, 20 tetranorprostaglandin f2 alpha'/exp OR '16 (3 
trifluoromethylphenoxy) 17, 18, 19, 20 tetranorprostaglandin f2 alpha' OR '17, 18, 19, 
20 tetranor 16 (3 trifluoromethylphenoxy) prostaglandin f2 alpha'/exp OR '17, 18, 19, 20 
290 
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tetranor 16 (3 trifluoromethylphenoxy) prostaglandin f2 alpha' OR '9alpha, 11alpha, 
15alpha trihydroxy 16 [3 (trifluoromethyl) phenoxy] 17, 18, 19, 20 tetranorprosta 5, 13 
dienoic acid'/exp OR '9alpha, 11alpha, 15alpha trihydroxy 16 [3 (trifluoromethyl) 
phenoxy] 17, 18, 19, 20 tetranorprosta 5, 13 dienoic acid' OR 'al 5848'/exp OR 'al 5848' 
OR 'al5848'/exp OR 'al5848' OR 'equimate'/exp OR 'equimate' OR 'fluprostenol 
sodium'/exp OR 'fluprostenol sodium' OR 'ici 80, 008'/exp OR 'ici 80, 008' OR 'ici 
80008'/exp OR 'ici 80008' OR 'ici 81, 008'/exp OR 'ici 81, 008' OR 'ici 81008'/exp OR 'ici 
81008' OR 'ici80, 008'/exp OR 'ici80, 008' OR 'ici80008'/exp OR 'ici80008' OR 'prosta 5, 
13 dienoic acid, 9alpha, 11alpha, 15alpha trihydroxy 16 [3 (trifluoromethyl) phenoxy] 17, 
18, 19, 20 tetranor'/exp OR 'prosta 5, 13 dienoic acid, 9alpha, 11alpha, 15alpha 
trihydroxy 16 [3 (trifluoromethyl) phenoxy] 17, 18, 19, 20 tetranor' OR 'prostaglandin f2 
alpha, 17, 18, 19, 20 tetranor 16 (3 trifluoromethylphenoxy)'/exp OR 'prostaglandin f2 
alpha, 17, 18, 19, 20 tetranor 16 (3 trifluoromethylphenoxy)' 
#21 
'fenprostalene'/exp/mj OR 'fenprostalene'/syn OR 'fenprostalene'/exp OR 
'fenprostalene' OR '7 [3, 5 dihydroxy 2 (3 hydroxy 4 phenoxy 1 butenyl) cyclopentyl] 4, 
5 heptanedioic acid methyl ester'/exp OR '7 [3, 5 dihydroxy 2 (3 hydroxy 4 phenoxy 1 
butenyl) cyclopentyl] 4, 5 heptanedioic acid methyl ester' OR 'bovilene'/exp OR 
'bovilene' OR 'methyl 7 [3, 5 dihydroxy 2 (3 hydroxy 4 phenoxy 1 butenyl) cyclopentyl] 
4, 5 heptadienoate'/exp OR 'methyl 7 [3, 5 dihydroxy 2 (3 hydroxy 4 phenoxy 1 butenyl) 
cyclopentyl] 4, 5 heptadienoate' OR 'rs 84043'/exp OR 'rs 84043' OR 'rs84043'/exp OR 
'rs84043' OR 'synchrocept b'/exp OR 'synchrocept b' 
49 
#20 
'epostane'/exp/mj OR 'epostane'/syn OR 'epostane'/exp OR 'epostane' OR '2alpha 
cyano 4alpha, 5alpha epoxy 17beta hydroxy 4, 17 dimethylandrostan 3 one'/exp OR 
'2alpha cyano 4alpha, 5alpha epoxy 17beta hydroxy 4, 17 dimethylandrostan 3 one' OR 
'4, 17alpha dimethyltrilostane'/exp OR '4, 17alpha dimethyltrilostane' OR '4, 5 epoxy 17 
hydroxy 4, 17alpha dimethyl 3 oxo 5alpha androstane 2alpha carbonitrile'/exp OR '4, 5 
epoxy 17 hydroxy 4, 17alpha dimethyl 3 oxo 5alpha androstane 2alpha carbonitrile' OR 
'4alpha, 5alpha epoxy 17beta hydroxy 4, 17 dimethyl 3 oxoandrostane 2alpha 
carbonitrile'/exp OR '4alpha, 5alpha epoxy 17beta hydroxy 4, 17 dimethyl 3 
oxoandrostane 2alpha carbonitrile' OR 'trilostane, 4, 17alpha dimethyl'/exp OR 
'trilostane, 4, 17alpha dimethyl' OR 'win 32729'/exp OR 'win 32729' OR 'win32729'/exp 
OR 'win32729' 
146 
#19 
'carboprost' OR 'carboprost'/exp OR carboprost AND ('trometamol' OR 'trometamol'/exp 
OR trometamol) OR 'carboprost trometamol'/exp/mj OR 'carboprost trometamol'/syn 
OR 'carboprost trometamol'/exp OR 'carboprost trometamol' OR '15 methyldinoprost 
trometamol'/exp OR '15 methyldinoprost trometamol' OR '15 methyldinoprost 
trometamo' OR '15 methylprostaglandin f2 alpha trometamol'/exp OR '15 
methylprostaglandin f2 alpha trometamol' OR 'carboprost tromethamine'/exp OR 
'carboprost tromethamine' OR 'carboprost tromethamol'/exp OR 'carboprost 
tromethamol' OR 'hemabate'/exp OR 'hemabate' OR 'u 32921 e'/exp OR 'u 32921 e' 
OR 'u 32921e'/exp OR 'u 32921e' OR 'u32921e'/exp OR 'u32921e' OR 'dilapan'/exp OR 
'dilapan' 
239 
#18 
'carboprost' OR 'carboprost'/exp OR carboprost AND methyl OR 'carboprost 
methyl'/exp/mj OR 'carboprost methyl'/syn OR 'carboprost methyl'/exp OR 'carboprost 
methyl' OR '15 methyldinoprost methyl ester'/exp OR '15 methyldinoprost methyl ester' 
OR '15 methylprostaglandin f2 alpha methyl ester'/exp OR '15 methylprostaglandin f2 
393 
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alpha methyl ester' OR '15 methylprostaglandin f2alpha methyl ester'/exp OR '15 
methylprostaglandin f2alpha methyl ester' OR 'pg 05'/exp OR 'pg 05' OR 'pg05'/exp OR 
'pg05' OR 'prostaglandin f2 alpha methyl ester, 15 methyl'/exp OR 'prostaglandin f2 
alpha methyl ester, 15 methyl' OR 'u 36384'/exp OR 'u 36384' OR 'u36384'/exp OR 
'u36384' 
#17 
carboprost OR 'carboprost'/exp/mj OR 'carboprost'/syn OR 'carboprost'/exp OR 
'carboprost' OR '15 methyldinoprost'/exp OR '15 methyldinoprost' OR '15 
methylprostaglandin f2 alpha'/exp OR '15 methylprostaglandin f2 alpha' OR '9, 11, 15 
trihydroxy 15 methylprosta 5, 13 dien 1 oic acid'/exp OR '9, 11, 15 trihydroxy 15 
methylprosta 5, 13 dien 1 oic acid' OR 'methylprostaglandin f2 alpha'/exp OR 
'methylprostaglandin f2 alpha' OR 'prostaglandin f2 alpha, 15 methyl'/exp OR 
'prostaglandin f2 alpha, 15 methyl' OR 'prostin 15m'/exp OR 'prostin 15m' OR 'prostin 
m'/exp OR 'prostin m' OR 'prostinfenem'/exp OR 'prostinfenem' OR 'u 32921'/exp OR 'u 
32921' OR 'u32921'/exp OR 'u32921' 
859 
#16 
uterotonic AND agent OR 'uterotonic agent'/exp/mj OR 'uterotonic agent'/syn OR 
'uterotonic agent'/exp OR 'uterotonic agent' 
80,869 
#15 
'prostaglandin'/exp/mj OR 'prostaglandin'/syn OR 'prostaglandin'/exp OR 'prostaglandin' 
506,910 
#14 
'prostaglandin' OR 'prostaglandin'/exp OR prostaglandin AND derivative OR 
'prostaglandin derivative'/exp/mj OR 'prostaglandin derivative'/exp OR 'prostaglandin 
derivative' OR '16, 16 dimethylprostaglandin'/exp OR '16, 16 dimethylprostaglandin' OR 
'8 methylprostaglandin derivative'/exp OR '8 methylprostaglandin derivative' OR 
'dimethylprostaglandin'/exp OR 'dimethylprostaglandin' OR 'methylprostaglandin'/exp 
OR 'methylprostaglandin' OR 'prostaglandin 1'/exp OR 'prostaglandin 1' OR 
'prostaglandin analog'/exp OR 'prostaglandin analog' OR 'prostaglandins, synthetic'/exp 
OR 'prostaglandins, synthetic' 
406,689 
#13 
'prostaglandin' OR 'prostaglandin'/exp OR prostaglandin AND f OR 'prostaglandin 
f'/exp/mj OR 'prostaglandin f'/syn OR 'prostaglandin f'/exp OR 'prostaglandin f' OR 'pgf; 
prostaglandins f' OR 'prostaglandins f, synthetic'/exp OR 'prostaglandins f, synthetic' 
94,258 
#12 
'prostaglandin'/exp OR prostaglandin AND e OR 'prostaglandin e'/exp/mj OR 
'prostaglandin e'/syn OR 'prostaglandin e'/exp OR 'prostaglandin e' OR 'pge; 
prostaglandins e' OR 'prostaglandins e, synthetic'/exp OR 'prostaglandins e, synthetic' 
149,126 
#11 
prostaglandins OR 'prostaglandins'/exp/mj OR 'prostaglandins'/syn OR 
'prostaglandins'/exp OR 'prostaglandins' 
506,910 
#10 
#2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 
365,238 
#9 
'labor' OR 'labor'/exp OR labor AND stage AND 3 OR 'labor stage 3'/exp/mj OR 'labor 
stage 3'/syn OR 'labor stage 3'/exp OR 'labor stage 3' OR 'delivery stage 3'/exp OR 
'delivery stage 3' OR 'delivery stage iii'/exp OR 'delivery stage iii' OR 'labor stage iii'/exp 
OR 'labor stage iii' OR 'labor stage, third'/exp OR 'labor stage, third' OR 'labour stage 
3'/exp OR 'labour stage 3' OR 'labour stage iii'/exp OR 'labour stage iii' OR 'third 
delivery stage'/exp OR 'third delivery stage' OR 'third labor stage'/exp OR 'third labor 
stage' OR 'third labour stage'/exp OR 'third labour stage' OR 'third stage of delivery'/exp 
6,245 
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OR 'third stage of delivery' OR 'third stage of labor'/exp OR 'third stage of labor' OR 
'third stage of labour'/exp OR 'third stage of labour' 
#8 
'uterus' OR 'uterus'/exp OR uterus AND ('bleeding' OR 'bleeding'/exp OR bleeding) OR 
'uterus bleeding'/exp/mj OR 'uterus bleeding'/syn OR 'uterus bleeding'/exp OR 'uterus 
bleeding' OR 'bleeding, uterus'/exp OR 'bleeding, uterus' OR 'hemorrhage, uterine'/exp 
OR 'hemorrhage, uterine' OR 'uterine bleeding'/exp OR 'uterine bleeding' OR 'uterine 
haemorrhage'/exp OR 'uterine haemorrhage' OR 'uterine hemorrhage'/exp OR 'uterine 
hemorrhage' OR 'uterus haemorrhage'/exp OR 'uterus haemorrhage' OR 'uterus 
hemorrhage'/exp OR 'uterus hemorrhage' 
30,189 
#7 
genital AND ('bleeding' OR 'bleeding'/exp OR bleeding) OR 'genital bleeding'/exp/mj 
OR 'genital bleeding'/syn OR 'genital bleeding'/exp OR 'genital bleeding' OR 'genital 
haemorrhage'/exp OR 'genital haemorrhage' OR 'genital hemorrhage'/exp OR 'genital 
hemorrhage' 
67,118 
#6 
postpartum AND ('hemorrhage' OR 'hemorrhage'/exp OR hemorrhage) OR 'postpartum 
hemorrhage'/exp/mj OR 'postpartum hemorrhage'/exp OR 'postpartum hemorrhage' OR 
'fluxus postpartum'/exp OR 'fluxus postpartum' OR 'hemorrhage, postpartum'/exp OR 
'hemorrhage, postpartum' OR 'post partum hemorrhage'/exp OR 'post partum 
hemorrhage' OR 'postpartal hemorrhage'/exp OR 'postpartal hemorrhage' OR 
'postpartum bleeding'/exp OR 'postpartum bleeding' OR 'postpartum haemorrhage'/exp 
OR 'postpartum haemorrhage' OR 'puerperal hemorrhage'/exp OR 'puerperal 
hemorrhage' OR 'secondary postpartum hemorrhage'/exp OR 'secondary postpartum 
hemorrhage' 
7,498 
#5 
obstetric AND ('hemorrhage' OR 'hemorrhage'/exp OR hemorrhage) OR 'obstetric 
hemorrhage'/exp/mj OR 'obstetric hemorrhage'/syn OR 'obstetric hemorrhage'/exp OR 
'obstetric hemorrhage' OR 'hemorrhage, obstetric'/exp OR 'hemorrhage, obstetric' OR 
'obstetric haemorrhage'/exp OR 'obstetric haemorrhage' OR 'obstetrical 
haemorrhage'/exp OR 'obstetrical haemorrhage' OR 'obstetrical hemorrhage'/exp OR 
'obstetrical hemorrhage' 
192,382 
#4 
'labor' OR 'labor'/exp OR labor AND ('complication' OR 'complication'/exp OR 
complication) OR 'labor complication'/exp/mj OR 'labor complication'/syn OR 'labor 
complication'/exp OR 'labor complication' OR 'labor complications'/exp OR 'labor 
complications' OR 'obstetric labor complications'/exp OR 'obstetric labor complications' 
114,734 
#3 
'placenta' OR 'placenta'/exp OR placenta AND disorder OR 'placenta disorder'/exp/mj 
OR 'placenta disorder'/syn OR 'placenta disorder'/exp OR 'placenta disorder' OR 
'placenta disease'/exp OR 'placenta disease' OR 'placenta diseases'/exp OR 'placenta 
diseases' OR 'placenta dysfunction'/exp OR 'placenta dysfunction' OR 'placental 
dysfunction'/exp OR 'placental dysfunction' 
44,448 
#2 
retained AND ('placenta' OR 'placenta'/exp OR placenta) OR 'retained placenta'/exp/mj 
OR 'retained placenta'/syn OR 'retained placenta'/exp OR 'retained placenta' OR 
'placenta retention'/exp OR 'placenta retention' OR 'placenta, retained'/exp OR 
'placenta, retained' 
1,659 
#1 
'crossover procedure'/exp/mj OR 'crossover procedure'/exp OR 'crossover procedure' 
642,282 
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OR 'double blind procedure'/exp OR 'double blind procedure' OR 'randomized 
controlled trial'/exp OR 'randomized controlled trial' OR 'single-blind procedure'/exp OR 
'single-blind procedure' OR 'random allocation'/exp OR 'random allocation' OR 
'random$' OR 'factorial$' OR 'crossover$' OR 'placebo$' OR 'placebo'/exp OR 'placebo' 
OR 'crossover' OR 'factorial' OR 'randomization'/exp OR 'randomization' NOT ('animal' 
OR 'animal'/exp OR animal OR 'animals' OR 'animals'/exp OR animals) 
 
 
Central database 
Search Date: 17/05/2011 
 
Cochrane Reviews [20] Other Reviews [8]  Clinical Trials [283]  Methods Studies [0]  
Technology Assessments [1]  Economic Evaluations [4]  Cochrane Groups [0] 
 
 
ID Search Hits 
#1 "prostaglandins" OR "prostanoids" 2651 
#2 
"dinoprostone" OR "PGE2 alpha" OR "alpha, PGE2" OR "PGE2alpha" OR 
"Prostaglandin E2 alpha" OR "alpha, Prostaglandin E2" OR "Prostaglandin 
E2alpha" OR "PGE2" OR "Prostaglandin E2" OR "E2, Prostaglandin" OR "Prepidil 
Gel" OR "Prostenon" :ti,ab,kw 
1936 
#3 "prostaglandin F1" OR "PGF1" OR "prostaglandin F1alpha" OR "PGF1alpha" OR "PGF1 alpha" :ti,ab,kw 318 
#4 "prostaglandin E2 methyl ester" OR "PGE2 methyl ester" :ti,ab,kw 5 
#5 
"dinoprost" OR "PGF2" OR "Prostaglandin F2alpha" OR "F2alpha, Prostaglandin" 
OR "PGF2alpha" OR "Prostaglandin F2" OR "Prostaglandin F2 alpha" OR "F2 
alpha, Prostaglandin" OR "9alpha,11beta-PGF2" OR "9alpha,11beta PGF2" OR 
"PGF2 alpha" OR "alpha, PGF2" OR "Estrofan" OR "Enzaprost F" :ti,ab,kw 
645 
#6 "Oxytocics" :ti,ab,kw 599 
#7 "Prostaglandins, Synthetic" OR "Synthetic Prostaglandins" OR "PG Analogs" OR "Prostaglandin Analogues" OR "Prostaglandin Analogs" :ti,ab,kw 152 
#8 "misoprostol" OR "SC-29333" OR "SC 29333" OR "SC29333" OR "SC-30249" OR "SC 30249" OR "Cytotec" :ti,ab,kw 1567 
#9 "Carboprost" OR "15-Methylprostaglandin F2alpha" OR "15 Methylprostaglandin F2alpha" OR "15(S)-15-Methyl PGF2alpha" :ti,ab,kw 54 
#10 "Abortifacient Agents, Nonsteroidal" :ti,ab,kw 414 
#11 "fenprostalene" :ti,ab,kw 0 
#12 "meteneprost" OR "9-methylene-PGE2" OR "9-methylene-16,16-dimethyl PGE2" OR "9-deoxo-16,16-dimethyl-9-methylene-PGE2" :ti,ab,kw 20 
#13 
"sulprostone" OR "sulproston" OR "methylsulfonylamide" OR "16-phenoxy-
omega-17,18,19,20-tetranor-PGE2 methylsulfonylamide" OR "ZK-57671" OR 
"SHB 286" OR "CP-34089" OR "Nalador" :ti,ab,kw 
74 
#14 "Prostaglandins F" OR "PGF" :ti,ab,kw 706 
#15 
"Prostaglandins E, Synthetic" OR "Synthetic Prostaglandins E" OR "PGE 
Synthetic" OR "Prostaglandin E Analogues" OR "Prostaglandin E Analogs" 
:ti,ab,kw 
174 
#16 "Prostaglandins E" OR "PGE" :ti,ab,kw 752 
#17 "F2-Isoprostanes" OR "F2 Isoprostanes" OR "F2-Isoprostane" OR "F2 Isoprostane" :ti,ab,kw 144 
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#18 "prostaglandin E1 methyl ester" OR "PGE(1) methyl ester" OR "PGE1 methyl ester" OR "Prostaglandin E(1) methyl ester" :ti,ab,kw 22 
#19 "prostaglandin E2 ethanolamide" OR "PGE(2) ethanolamide" OR "Prostaglandin E(2) ethanolamide" :ti,ab,kw 0 
#20 "6-keto-prostaglandin F2alpha" OR "6-keto-prostaglandin F2 alpha" OR "6-keto-PGF2alpha" :ti,ab,kw 1 
#21 "gemeprost" OR "Cervagem" OR "Cergem" OR "ONO 802" OR "ONO-802" OR "PG802" :ti,ab,kw 120 
#22 "Prostaglandin F2alpha ethanolamide" OR "PGF(2alpha) 1-ethanolamide" OR "Prostamide F(2alpha)" 0 
#23 "2,3-dinor-8-iso-prostaglandin-F(2alpha)" :ti,ab,kw 0 
#24 "2,3-dinor-5,6-dihydro-8-iso-prostaglandin F2(alpha)" OR "2,3-dinor-5,6-dihydro-8-iso-PGF2alpha" :ti,ab,kw 1 
#25 
"17-phenyl-18,19,20-trinor-prostaglandin F2 alpha-1-isopropyl ester" OR 
"PhDH100A" OR "17-phenyl-18,19,20-trinor-PGF2alpha-1-isopropyl ester" 
:ti,ab,kw 
2 
#26 "16-methyl prostaglandin E2" OR "16-methyl PGE2" :ti,ab,kw 0 
#27 
"Dinoprost tromethamine" OR "PGF2alpha tromethamine" OR "prostaglandin 
F2alpha tromethamine" OR "Lutalyse" OR "Minprostin F2 Alpha" OR "Prostin F2" 
OR "Prostin F2 Alpha" :ti,ab,kw 
0 
#28 "Carboprost tromethamine" OR "carboprost trometamol" OR "Hemabate" :ti,ab,kw 9 
#29 
(#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR 
#12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 
OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28) 
6225 
#30 "Placenta Diseases" OR "Placental Diseases" OR "Disease, Placental" OR "Placental Disease" OR "Placenta Disorders" :ti,ab,kw 37 
#31 ("Placenta" AND "retained") OR "Placenta, retained" OR "retained placenta" OR "Retained Placentas" OR "Retained Placenta" :ti,ab,kw 85 
#32 "Obstetric Labor Complications" OR "Labor Complications" OR "Labor Complication" :ti,ab,kw 404 
#33 "postpartum hemorrhage" OR "Immediate Postpartum Hemorrhage" OR "Delayed Postpartum Hemorrhage" :ti,ab,kw 329 
#34 "puerperal disorders" OR "Puerperal Disorder" :ti,ab,kw 245 
#35 "uterine hemorrhage" OR "Uterine Bleeding" OR "Uterine Bleedings" OR "Uterine Hemorrhages" :ti,ab,kw 751 
#36 "labor stage, third" OR "Third Labor Stage" OR "Third Stage Labor" :ti,ab,kw 140 
#37 (#30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36) 1784 
#38 (#29 AND #37) 316 
 
 
  
 
African index medicus  
Search Date: 22/05/2011 
http://indexmedicus.afro.who.int/cgi-
bin/wxis.exe/iah/?IsisScript=iah/iah.xis&lang=I&base=AIM 
 
Advanced form Keywords contains: ("RETAINED" and "PLACENTA") or 
("RETAINED" and "PLACENTAE") or ("RETAINED" and "PLACENTAL") or 
("RETAINED" and "PLACENTAIRE" ) or ("RETAINED" and "PLACENTAR") 
Total: 3 
 
 
Australian medical index  
Search Date: 22/05/2011 
http://catalogue.nla.gov.au/Record/2613918 
 
Advance search Keywords contains ALL OF THESE in ALL FIELDS: “placenta  
retained”  OR Keywords contains AS A PHRASE in ALL FIELDS: "Placenta, 
retained" OR  "retained placenta" OR "retained placentas"  
Total 01 
 
Index medicus for the eastern mediterranean region 
Search Date: 22/05/2011 
http://www.emro.who.int/Library/Databases/wxis.exe/Library/Databases/iah/?IsisS
cript=iah/iah.xic&base=imemr&lang=i 
 
Advance search Keywords contains: ("RETAINED" and "PLACENTA") or 
("RETAINED" and "PLACENTAE") or ("RETAINED" and "PLACENTAL") or ( 
"RETAINED" and "PLACENTAIRE" ) or ("RETAINED" and "PLACENTAR") 
Total: 42 
 
IndMED 
Search Date: 22/05/2011 
http://indmed.nic.in/indmed.html 
Advance search Keywords contains ANY WHERE: (Placenta  AND retained) 
OR (Placenta, retained) OR (Retained AND Placentas)  
Total: 08 
 
 
KoreaMed 
Search Date: 22/05/2011 
http://www.koreamed.org/SearchBasic.php 
Keywords contains ALL:  “placenta” AND “retained” 
Total: 14  
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Bireme  
Search Date: 22/05/2011 
http://regional.bvsalud.org/php/index.php?lang=es 
Búsqueda vía descriptores DeCS/MeSH TODOS LOS ÍNDICES TODAS LAS 
FUENTES:"Retención de la Placenta" OR “Placenta retenida” 
Total: 426 
 
 
SciELO 
Search Date: 22/05/2011 
http://www.scielo.org/php/index.php 
Advance search Keywords contains TODOS LOS ÍNDICES REGIONAL: 
(Placenta  AND retained) OR "Placenta, retained" OR "retained placenta" OR 
"Retained Placentas"  
Total: 08 
 
Advance search Palabras claves en Español TODOS LOS ÍNDICES REGIONAL: 
(Placenta  AND retenida) OR "Placenta, retenida" OR "retención de placenta" OR 
"retención de la placenta" 
Total: 0 
 
ScieELO 
Search Date: 22/05/2011 
Google plataform: (retención de placenta) site:http://www.scielo.cl OR 
site:http://www.scielo.org.pe OR site:http://www.scielo.org.ar OR 
site:http://www.scielo.br OR site:http://www.scielo.org.co OR 
site:http://scielo.sld.cu OR site:http://scielo.isciii.es OR 
site:http://www.scielo.oces.mctes.pt OR site:http://www.scielo.org.ve OR 
site:http:// www.scielo.org.mx OR site:http://www.scielo.sa.cr OR 
site:http://scielo.iics.una.py OR site:http://caribbean.scielo.org OR 
site:http://www.scielo.org.pe OR site:http://www.scielo.edu.uy OR 
site:http://www.scielosp.org OR site:http:// socialsciences.scielo.org  
Total: 33 
 
Google plataform: (placenta retenida) site:http://www.scielo.cl OR 
site:http://www.scielo.org.pe OR site:http://www.scielo.org.ar OR 
site:http://www.scielo.br OR site:http://www.scielo.org.co OR 
site:http://scielo.sld.cu OR site:http://scielo.isciii.es OR 
site:http://www.scielo.oces.mctes.pt OR site:http://www.scielo.org.ve OR 
site:http:// www.scielo.org.mx OR site:http://www.scielo.sa.cr OR 
site:http://scielo.iics.una.py OR site:http://caribbean.scielo.org OR 
site:http://www.scielo.org.pe OR site:http://www.scielo.edu.uy OR 
site:http://www.scielosp.org OR site:http://  
socialsciences.scielo.org 
Total: 4 
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Index medicus for the south east asian region 
Search Date: 22/05/2011 
http://imsear.hellis.org/advanced-search 
Advance search Keywords contains TODO DSpace: ("placenta, retained") OR 
("retained placenta") OR ("retained placentas") OR ("retained placenta") OR 
(placenta  AND retained)  
Total: 11 
 
Panteleimon 
Search Date: 22/05/2011 
http://www.panteleimon.org 
Keywords or Phrase contains in English: “placenta” AND “retained”  OR 
Keywords or Phrase contains in Russian: “плацента” AND “Удержанных” OR 
Keywords or Phrase contains in Ukrainian: “ПЛАЦЕНТИ” AND “Утриманих” 
Total: 0 
 
Western pacific region index medicus 
Search Date: 22/05/2011 
http://www.wprim.org/ 
Advance search Keywords contains DEFAULT: (Placenta  AND retained) OR 
"Placenta, retained" OR "retained placenta" OR "Retained Placentas"  
Total:16 
 
Scopus 
Search Date: 30/05/2011 
Keywords contains IN ALL FIELDS: ("Placenta" AND "retained") OR 
"Placenta,retained" OR "retained placenta" OR "retained placentas" 
Total: 3,562 
 
Web of Science ISI 
Search Date: 30/05/2011 
Keywords contains TOPIC:(Placent* AND retained) OR (Placenta, retained) OR 
(Retained Placentas) OR (retained placenta) 
Total: 673  
 
Dissertation.com 
Search Date: 30/05/2011 
http://www.dissertation.com/index.php 
Keywords contains: ("Placenta"  AND "retained") OR "Placenta, retained" OR 
"retained placenta" OR "Retained Placentas"  
Total: 0 
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Dissonline.de 
Search Date: 30/05/2011 
http://www.dissonline.de/eng/index.htm 
Keywords contains: (Placenta, retained) OR (retained AND placenta) 
Total: 0 
 
Keywords contains in German: “plazentaretention” OR “Retentio placentae” 
Total:13 
 
Openthesis.org 
Search Date: 30/05/2011 
http://www.openthesis.org/advancedSearch.html 
Keywords contains: (Placenta AND retained) OR (Placenta, retained) OR 
(retained placenta) OR (Retained Placentas) AND (humans OR human)  
Total: 133 
 
Australian Digital Theses Programn 
Search Date: 30/05/2011 
http://trove.nla.gov.au/?q&adv=y 
Keywords contains: ("Placenta" AND "retained") OR "Placenta, retained" OR 
"retained placenta" OR "Retained Placentas"  
Conference paper Total: 24. Thesis total: 20. Conference proceedings Total: 
3. ReportsTotal: 39. 
 
OpenSIGLE 
Search Date: 30/05/2011 
http://opensigle.inist.fr/advanced-search 
Keywords contains: ((Placenta  AND retained) OR (Placenta, retained) OR 
(retained placenta) OR (Retained Placentas))  AND (human OR humans) 
Total: 47 
 
Proquest 
Search Date: 30/05/2011 
Advance search Keywords contains CITATION ABSTRACT: ((Placenta  AND 
retained) OR “Placenta, retained" OR "retained placenta" OR "Retained 
Placentas" )  
Total: 315  
 
 MetaRegister 
Search Date: 27/09/2011 
Keywords contains: “Placenta” OR “Placenta, retained" OR "retained placenta" 
OR "Retained Placentas"   
Total: 420 
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WHO Portal International Clinical Trials  Registry  
Search Date: 16/09/2011 
Keywords contains: “Placenta” OR “Placenta, retained" OR "retained placenta" 
OR "Retained Placentas"   
Total: 94 
 
Appendix 2. Kappa Statistic 
Review Autor 2 
Review  
Author 1 
Kappa 
statistic 
Include Exclude Unsure Total 
Include 3           a 0           b 0            c 3         I1
Exclude 0           d 11756       e 0            f 11756    E1
Unsure 0           g 1           h 0            i 1       U1
Total 3          I2 11757     E2 0        U2 11760    K
 
Suppose the K studies are distributed according to numbers a to i as in table, then:  
Kappa: PO-PE / 1- PE 
Where 
Po:  a + e + i / K 
Then: 
Po:  3 + 11756 + 0 / 11760 
Po:  0.9999 
Where 
PE: I1 x I2 + E1 x E2 + U1 x U2 / K² 
Then: 
PE: 3 x 3 + 11756 x 11757 + 1 x 0 / 11760² 
PE: 9 + 138215292 + 0 / 138297600 
PE: 9 + 138215292 + 0 / 138297600 
PE: 0.9994 
Where 
Kappa: PO-PE / 1- PE 
Kappa: 0.9999 - 0.9994 / 1 - 0.9994 
Kappa: 0.833 
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LITERATURE SEARCH
 
Databases:  MEDLINE, EMBASE, CENTRAL, AIM, AMI, IMEMR, IndMED, KoreaMed, LILACS, Scielo, IBECS,
IMSEAR, Panteleimon and WPRIM. 
 
Conference proceedings, dissertations and thesis: Scopus, Web of Knowledge, Proquest, dissertation.com,
dissonline.de, openthesis.org and ADTP.  
Search Results Combined (n:13016) 
Articles screened on basis of title and 
abstract after eliminated multiple publications 
Excluded (n:11728)  
Reasons 
Irrelevant 9477        
Different Population 7 
No Humans 1534      
 Included (n:32) 
 Manuscript review and application of inclusion 
criteria 
 Included (n:3) 
Sulproston
e 
Misoprost
ol 
Excluded (n:29) 
Reasons 
Were not randomized controlled 
trial 13  Prostaglandin 
F2 
  
 
Prostaglandins for management of retained placenta 
Patient or population: patients with management of retained placenta 
Settings: All care setting 
Intervention: Prostaglandins 
Outcomes Illustrative comparative risks* 
(95% CI) 
Relative 
effect 
(95% CI)
No of 
Participants 
(studies) 
Quality of 
the evidence 
(GRADE) 
Comments
Assumed 
risk 
Corresponding risk 
 Control Prostaglandins   
Maternal Transfusion 
Requirement of Maternal 
Transfusion 
Study population RR 0.81 
(0.33 to 
2) 
50 
(1 study) 
 
very low1,2,3,4 
 
308 per 
1000 
249 per 1000 
(102 to 615) 
Moderate 
  
Expulsion of the placenta 
without manual removal 
Expulsion of the placenta into 30 
minutes after 
intervention/Expulsion of the 
placenta without manual removal 
Follow-up: mean 30 minutes after 
medical intervention 
Study population RR 2.53 
(1.66 to 
3.86) 
132 
(3 studies) 
 
very 
low2,4,5,6,7 
 
260 per 
1000 
657 per 1000 
(431 to 1000) 
Moderate 
  
Estimated Blood Loss  
Estimated blood loss / Estimated 
blood loss in milliliters 
Follow-up: mean 30 Between 
intervention and the delivery of 
placenta 
 The mean estimated 
blood loss in the 
intervention groups was 
258.04 lower 
(771.49 lower to 255.4 
higher) 
 87 
(2 studies) 
 
very 
low2,4,5,8,9 
 
Duration of third stage of labour 
Duration of third stage of 
labour/Duration of third stage of 
labour in minutes after medical 
intervention  
Follow-up: 45 to 75 minutes 
between new born birth and 
medical intervention 
 The mean estimated 
duration of third stage of 
labour in the intervention 
groups was 
3.60 lower 
(21.57 lower to 14.37 
higher) 
 54 
(1 study) 
 
very 
low2,4,10,11 
 
Time for delivery of the placenta 
Time for delivery of the placenta/ 
Time for delivery of the placenta in 
minutes 
Follow-up: 0 to 30 minutes after 
medical intervention 
 The mean estimated time 
for delivery of the 
placenta in the 
intervention groups was 
6.50 lower 
(11.19 lower to 1.81 
lower) 
 21 
(1 study) 
 
very 
low2,4,12,13 
 
Painful Contractions 
Painful contractions/ subjectively 
assessed 
Follow-up: 0 to 30 minutes after 
meedical intervention 
Study population RR 2.12 
(0.71 to 
6.32) 
87 
(2 studies) 
 
very 
low2,4,14,15,16 
 
94 per 
1000 
200 per 1000 
(67 to 596) 
Moderate 
  
Fever or sickness or vomiting or 
diarrhea or dizziness or flushes 
Fever or sickness or vomiting or 
diarrhea or dizziness or flushes/ 
subjectively assessed 
Follow-up: 0 to 30 minutes afet 
medical intervention 
Study population RR 0.56 
(0.12 to 
2.49) 
87 
(2 studies) 
 
very 
low2,4,14,17,18 
 
113 per 
1000 
63 per 1000 
(14 to 282) 
Moderate 
  
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The 
corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the 
relative effect of the intervention (and its 95% CI). 
 
CI: Confidence interval; RR: Risk ratio;  
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect.  
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Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may 
change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is 
likely to change the estimate. 
Very low quality: We are very uncertain about the estimate. 
1 Critical limitation for two criteria (Incomplete outcome data and other risk of bias) dowgrade level of evidence.The study 
reported an â€œAs-treatedâ€ analysis, they only included the results from those patients who had both been assigned 
randomly and who had actually received the trial medication, besides, the trial was stopped early due to apparent benefit.  
2 The applicability of the evidence outside the research setting is limited however these studies were all conducted in clinical 
settings that are quite similar. The interventions in the review are not available.  
3 Total exposed 26 non exposed 24. Total events: 8 (exposed), 6 (non exposed) RR 0.81 [0.33,2.00] Confidence interval do 
include null effect and do include appreciable harm or benefit. No optimal information size. 
4 The likelihood of publication bias was not assessed.  
5 Critical limitation for three criteria (Blinding of participants and personnel, Incomplete outcome data and Other risk of bias) 
dowgrade level of evidence. 
6 No large variation in effect. Confidence intervals do overlap. Statistical test for heterogeneity (P<0.00001) I2 =0%.  
7 Total exposed 77 non exposed 55. Total events: 20 (exposed), 35 (non exposed) RR 2.53 [1.66,3.86] Confidence interval 
donot include null effect and do not include appreciable harm or benefit. No optimal information size. 
8 Large variation in effect. Confidence intervals do not overlap. Statistical test for heterogeneity (P<0.004) I2 =88%.  
9 Total exposed 53 non exposed 34. No optimal information size. 
10 Critical limitation for two criteria (Blinding of participants and personnel and other risk of bias) dowgrade level of evidence.
11 Total exposed 33 non exposed 21. No optimal information size. 
12 Critical limitation for two criteria (Allocation concealment and blinding of participants and personnel) dowgrade level of 
evidence. 
13 Total exposed 11 non exposed 10. No optimal information size. 
14 Critical limitation for four criteria (Allocation concealment, Blinding of participants and personnel, Incomplete outcome data 
and other risk of bias) dowgrade level of evidence. 
15 No large variation in effect. Confidence intervals do overlap. Statistical test for heterogeneity (P 0.65) I2 =0%.  
16 No explanation was provided 
17 No large variation in effect. Confidence intervals do overlap. Statistical test for heterogeneity (P0.56) I2 =0%.  
18 Total exposed 53 non exposed 34. Total events: 6 (exposed), 2 (non exposed) RR 0.56 [0.12,2.49] Confidence interval do 
include null effect and do include appreciable harm or benefit. No optimal information size. 
 
